gamma-aminobutyric acid has been researched along with Depression in 237 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Neuropathic pain (NP) may facilitate ED, because it is frequently associated with anxiety, depression, and its drug, pregabalin, may also contribute ED." | 9.19 | Association between neuropathic pain, pregabalin treatment, and erectile dysfunction. ( Atar, M; Bozkurt, M; Bozkurt, Y; Daggulli, M; Em, S; Gocmez, C; Ozbey, I; Soylemez, H; Yildiz, M, 2014) |
| "The objective of this study was to determine whether pregabalin treatment for patients with neuropathic pain promotes erectile dysfunction." | 9.19 | Association between neuropathic pain, pregabalin treatment, and erectile dysfunction. ( Atar, M; Bozkurt, M; Bozkurt, Y; Daggulli, M; Em, S; Gocmez, C; Ozbey, I; Soylemez, H; Yildiz, M, 2014) |
| " Our goal was to compare the effects of gabapentin and pregabalin on improving sleep quality and depression among hemodialysis patients with PPN." | 9.17 | Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. ( Atalay, H; Biyik, Z; Gaipov, A; Guney, F; Solak, Y; Turk, S, 2013) |
| "Treatment with trazodone significantly improved global fibromyalgia severity, sleep quality, and depression, as well as pain interference with daily activities although without showing a direct effect on bodily pain." | 9.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| "Although trazodone is frequently used by fibromyalgia patients, its efficacy on this disease has not been adequately studied." | 9.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| " Trazodone, flexibly dosed (50-300 mg/day), was administered to 66 fibromyalgia patients during 12 weeks; 41 patients who completed the treatment accepted to receive pregabalin, also flexibly dosed (75-450 mg/day), added to trazodone treatment for an additional 12-week period." | 9.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| "Trazodone significantly improved fibromyalgia severity and associated symptomatology." | 9.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| " If effective, pregabalin, whose beneficial effects on pain and sleep quality in fibromyalgia have been demonstrated, could complement the antidepressant and anxiolytic effects of trazodone." | 9.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| "The purpose of this, open-label, non-comparative study, was to evaluate the efficacy on quality of life and the efficacy of gabapentin monotherapy in patients with chronic radiculopathy." | 9.14 | Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality. ( Deniz, O; Erdal, A; Gureser, G; Karatay, S; Senel, K; Ugur, M; Yildirim, K, 2009) |
| "Thirty-five patients with radicular pain and diagnosed as L4, L5 or S1 radiculopathy were treated with oral gabapentin from a total of 300 mg per day once up to a total of 1800 mg per day divided in 3 doses for eight-week trial period." | 9.14 | Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality. ( Deniz, O; Erdal, A; Gureser, G; Karatay, S; Senel, K; Ugur, M; Yildirim, K, 2009) |
| "Gabapentin may provide benefits in terms of alleviation of pain and overall quality of life in patients with chronic radiculopathy." | 9.14 | Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality. ( Deniz, O; Erdal, A; Gureser, G; Karatay, S; Senel, K; Ugur, M; Yildirim, K, 2009) |
| "The objective of this study was to evaluate the effect of patients' characteristics at baseline on the magnitude of pain response to pregabalin in patients with fibromyalgia." | 9.14 | Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics. ( Emir, B; Murphy, TK; Petersel, DL; Whalen, E, 2010) |
| "Data from four randomized, multicenter, placebo-controlled clinical studies of pregabalin in patients with fibromyalgia were used for the analysis." | 9.14 | Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics. ( Emir, B; Murphy, TK; Petersel, DL; Whalen, E, 2010) |
| "The magnitude of response to pregabalin in terms of changes in pain may depend on age, pain, and sleep levels at baseline in patients with fibromyalgia." | 9.14 | Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics. ( Emir, B; Murphy, TK; Petersel, DL; Whalen, E, 2010) |
| "Although escitalopram is known to be an effective drug for adult depression, its disease-modifying efficacy on adolescents remains controversial." | 8.31 | Effects of Escitalopram on the Functional Neural Circuits in an Animal Model of Adolescent Depression. ( Choi, JY; Han, SJ; Kang, KJ; Lee, N; Nam, KR; Oh, SJ, 2023) |
| "The administration of escitalopram had no therapeutic effect on the adolescent depression." | 8.31 | Effects of Escitalopram on the Functional Neural Circuits in an Animal Model of Adolescent Depression. ( Choi, JY; Han, SJ; Kang, KJ; Lee, N; Nam, KR; Oh, SJ, 2023) |
| "We studied the effects of low-dose ozone therapy on the sleep quality of patients with coronary heart disease (CHD) and insomnia by measuring the levels of brain-derived neurotrophic factor (BDNF) and GABA in blood serum." | 8.02 | Low-Dose Ozone Therapy Improves Sleep Quality in Patients with Insomnia and Coronary Heart Disease by Elevating Serum BDNF and GABA. ( Feng, X; Huang, H; Li, Y; Ren, H; Wang, Y; Yu, S, 2021) |
| "Gamma-aminobutyric acid (GABA) and glutamate neurotransmission have been implicated in the pathophysiology of depression and mechanistically linked to ketamine's antidepressant response." | 8.02 | A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration. ( Coombes, BJ; Frye, MA; Geske, JR; Lanza, IR; Morgan, RJ; Port, JD; Singh, B; Voort, JLV, 2021) |
| "This investigation indicated that pregabalin is safe and effective for reducing both LBP and mood disturbance in patients with depression." | 7.80 | Outcomes of pregabalin in lumbar-disease patients with depression. ( Ozaki, T; Sugimoto, Y; Takigawa, T; Tanaka, M; Tetsunaga, T, 2014) |
| "Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter of the central nervous system (CNS) in mammalian, which involved in several mood disorders such as anxiety, depression and schizophrenia." | 7.80 | [The interaction between gamma-aminobutyric acid and other related neurotransmitters in depression]. ( An, SC; Li, JN; Li, Z, 2014) |
| "The aim of this study was to investigate the relationship between plasma glutamate, glutamine and gamma-aminobutyric acid (GABA) levels in female patients with major depression treated with S-citalopram or fluoxetine." | 7.75 | The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. ( Calişkan, M; Gören, MZ; Kaplan, OK; Küçükibrahimoğlu, E; Saygin, MZ; Unsal, C, 2009) |
| "Our findings may suggest that GABA, glutamate and glutamine play a role in depression and that plasma GABA may be used as a biomarker for treatment control." | 7.75 | The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. ( Calişkan, M; Gören, MZ; Kaplan, OK; Küçükibrahimoğlu, E; Saygin, MZ; Unsal, C, 2009) |
| "Although studies have demonstrated the efficacy of the new anti-epileptic on the block, Pregabalin, in the treatment of Generalized Anxiety Disorder and Social Anxiety Disorder, there is no study so far of such efficacy for the treatment of depression." | 7.74 | Pregabalin in the treatment of depression. ( Showraki, M, 2007) |
| "Allopregnanolone treatment impacted significantly GABA metabolism, oxidative stress, and some of the mitochondria-related outcomes." | 6.90 | Allopregnanolone Treatment Improves Plasma Metabolomic Profile Associated with GABA Metabolism in Fragile X-Associated Tremor/Ataxia Syndrome: a Pilot Study. ( Carrillo, NR; Giulivi, C; Hagerman, RJ; Napoli, E; Rogawski, M; Schneider, A; Tassone, F; Trivedi, A; Wang, JY, 2019) |
| "Taking pregabalin for the treatment of neuropathic pain poses an increased risk for developing ED in male patients." | 6.79 | Association between neuropathic pain, pregabalin treatment, and erectile dysfunction. ( Atar, M; Bozkurt, M; Bozkurt, Y; Daggulli, M; Em, S; Gocmez, C; Ozbey, I; Soylemez, H; Yildiz, M, 2014) |
| "Treatment with trazodone significantly improved global fibromyalgia severity, sleep quality, and depression, as well as pain interference with daily activities although without showing a direct effect on bodily pain." | 6.76 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| " Trazodone, flexibly dosed (50-300 mg/day), was administered to 66 fibromyalgia patients during 12 weeks; 41 patients who completed the treatment accepted to receive pregabalin, also flexibly dosed (75-450 mg/day), added to trazodone treatment for an additional 12-week period." | 6.76 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| "Depression is a common psychiatric disorder and a leading cause of disability worldwide." | 6.55 | The role of gamma-aminobutyric acid in female depression ( Carvajal-Lohr, A; Flores-Ramos, M; Rodríguez-Bores, L; Salinas, M, 2017) |
| " Overall, pregabalin was well tolerated with no new adverse events emerging that have not been reported with its use in other indications." | 6.44 | Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome. ( Owen, RT, 2007) |
| " This was seen in the 150 mg/day, 300-450 mg/day and 600 mg/day dosing groups." | 6.44 | Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. ( Baldinetti, F; Baldwin, DS; Mandel, F; Stein, DJ, 2008) |
| "Seven patients with treatment-resistant depression enrolled in an open-label, feasibility trial of a single IV 40-min ketamine infusion during a functional MR spectroscopy (fMRS) scan utilizing a novel frequency adjusting MEGA-PRESS sequence." | 5.62 | A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration. ( Coombes, BJ; Frye, MA; Geske, JR; Lanza, IR; Morgan, RJ; Port, JD; Singh, B; Voort, JLV, 2021) |
| "Depression is one of the most common associated diseases, which aggravates psoriatic skin lesions and affects the life quality of patients." | 5.56 | Depressive-like behaviors in mice with Imiquimod-induced psoriasis. ( Di, T; Guo, J; Guo, X; Li, P; Liu, Y; Meng, Y; Qi, C; Wang, Y; Zhang, L; Zhao, J, 2020) |
| "Psoriasis is not only a chronic inflammatory skin disease but also a psychosomatic disorder." | 5.56 | Depressive-like behaviors in mice with Imiquimod-induced psoriasis. ( Di, T; Guo, J; Guo, X; Li, P; Liu, Y; Meng, Y; Qi, C; Wang, Y; Zhang, L; Zhao, J, 2020) |
| " We investigated the effect of long-term administration of ERI in three different doses on behavioral changes, hippocampal and prefrontal cortex (PFC) neurogenesis, and γ-aminobutyric acid (GABA)/glutamate balance in male Wistar rats exposed to chronic restraint stress (CRS)." | 5.48 | Behavioral effects of toll-like receptor-4 antagonist 'eritoran' in an experimental model of depression: role of prefrontal and hippocampal neurogenesis and γ-aminobutyric acid/glutamate balance. ( Aboul-Fotouh, S; Asaad, T; Ghanem, MH; Habib, M; Kassim, SK, 2018) |
| "Depression is the disease of the modern era." | 5.48 | Behavioral effects of toll-like receptor-4 antagonist 'eritoran' in an experimental model of depression: role of prefrontal and hippocampal neurogenesis and γ-aminobutyric acid/glutamate balance. ( Aboul-Fotouh, S; Asaad, T; Ghanem, MH; Habib, M; Kassim, SK, 2018) |
| "Pretreatment with spermine, considerably, reversed the PTZ induced alterations." | 5.46 | Protective effect of spermine against pentylenetetrazole kindling epilepsy induced comorbidities in mice. ( Kumar, M; Kumar, P, 2017) |
| "Spermine is an endogenous polyamine; possesses anti-oxidant property and has ability to modulate ion channels and NO synthase activity." | 5.46 | Protective effect of spermine against pentylenetetrazole kindling epilepsy induced comorbidities in mice. ( Kumar, M; Kumar, P, 2017) |
| "Symptoms consistent with bruxism are a common chief complaint in dental practice." | 5.30 | Antidepressant-induced bruxism successfully treated with gabapentin. ( Brown, ES; Hong, SC, 1999) |
| "A case of bruxism, anxiety, insomnia and tremor is reported in a man with bipolar disorder that developed a few days after he initiated venlafaxine therapy for depression." | 5.30 | Antidepressant-induced bruxism successfully treated with gabapentin. ( Brown, ES; Hong, SC, 1999) |
| " Neuropathic pain (NP) may facilitate ED, because it is frequently associated with anxiety, depression, and its drug, pregabalin, may also contribute ED." | 5.19 | Association between neuropathic pain, pregabalin treatment, and erectile dysfunction. ( Atar, M; Bozkurt, M; Bozkurt, Y; Daggulli, M; Em, S; Gocmez, C; Ozbey, I; Soylemez, H; Yildiz, M, 2014) |
| "The objective of this study was to determine whether pregabalin treatment for patients with neuropathic pain promotes erectile dysfunction." | 5.19 | Association between neuropathic pain, pregabalin treatment, and erectile dysfunction. ( Atar, M; Bozkurt, M; Bozkurt, Y; Daggulli, M; Em, S; Gocmez, C; Ozbey, I; Soylemez, H; Yildiz, M, 2014) |
| "It has been suggested that the anticonvulsant drug pregabalin may be useful in some anxiety disorders." | 5.19 | Effect of pregabalin augmentation in treatment of patients with combat-related chronic posttraumatic stress disorder: a randomized controlled trial. ( Baniasadi, M; Fayyazi Bordbar, MR; Hosseini, G; Mostafavi Toroghi, H; Rezaei Ardani, A, 2014) |
| "Pregabalin effectively reduced the severity of PTSD symptoms but it was not effective in improving the severity of depression, anxiety, and quality of life." | 5.19 | Effect of pregabalin augmentation in treatment of patients with combat-related chronic posttraumatic stress disorder: a randomized controlled trial. ( Baniasadi, M; Fayyazi Bordbar, MR; Hosseini, G; Mostafavi Toroghi, H; Rezaei Ardani, A, 2014) |
| " Our goal was to compare the effects of gabapentin and pregabalin on improving sleep quality and depression among hemodialysis patients with PPN." | 5.17 | Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial. ( Atalay, H; Biyik, Z; Gaipov, A; Guney, F; Solak, Y; Turk, S, 2013) |
| "Treatment with trazodone significantly improved global fibromyalgia severity, sleep quality, and depression, as well as pain interference with daily activities although without showing a direct effect on bodily pain." | 5.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| "Although trazodone is frequently used by fibromyalgia patients, its efficacy on this disease has not been adequately studied." | 5.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| " Trazodone, flexibly dosed (50-300 mg/day), was administered to 66 fibromyalgia patients during 12 weeks; 41 patients who completed the treatment accepted to receive pregabalin, also flexibly dosed (75-450 mg/day), added to trazodone treatment for an additional 12-week period." | 5.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| "Trazodone significantly improved fibromyalgia severity and associated symptomatology." | 5.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| " If effective, pregabalin, whose beneficial effects on pain and sleep quality in fibromyalgia have been demonstrated, could complement the antidepressant and anxiolytic effects of trazodone." | 5.15 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| " Pharmacological therapy consists of the recommended pharmacological treatment for fibromyalgia: pregabalin (300-600 mg/day), with duloxetine (60-120 mg/day) added where there is a comorbid depression)." | 5.14 | Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial. ( Alda, M; Andrés, E; del Hoyo, YL; García-Campayo, J; Luciano, JV; Magallón, R; Rodero, B; Serrano-Blanco, A, 2009) |
| "The purpose of this, open-label, non-comparative study, was to evaluate the efficacy on quality of life and the efficacy of gabapentin monotherapy in patients with chronic radiculopathy." | 5.14 | Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality. ( Deniz, O; Erdal, A; Gureser, G; Karatay, S; Senel, K; Ugur, M; Yildirim, K, 2009) |
| "Thirty-five patients with radicular pain and diagnosed as L4, L5 or S1 radiculopathy were treated with oral gabapentin from a total of 300 mg per day once up to a total of 1800 mg per day divided in 3 doses for eight-week trial period." | 5.14 | Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality. ( Deniz, O; Erdal, A; Gureser, G; Karatay, S; Senel, K; Ugur, M; Yildirim, K, 2009) |
| "Gabapentin may provide benefits in terms of alleviation of pain and overall quality of life in patients with chronic radiculopathy." | 5.14 | Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality. ( Deniz, O; Erdal, A; Gureser, G; Karatay, S; Senel, K; Ugur, M; Yildirim, K, 2009) |
| "The objective of this study was to evaluate the effect of patients' characteristics at baseline on the magnitude of pain response to pregabalin in patients with fibromyalgia." | 5.14 | Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics. ( Emir, B; Murphy, TK; Petersel, DL; Whalen, E, 2010) |
| "Data from four randomized, multicenter, placebo-controlled clinical studies of pregabalin in patients with fibromyalgia were used for the analysis." | 5.14 | Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics. ( Emir, B; Murphy, TK; Petersel, DL; Whalen, E, 2010) |
| "The magnitude of response to pregabalin in terms of changes in pain may depend on age, pain, and sleep levels at baseline in patients with fibromyalgia." | 5.14 | Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics. ( Emir, B; Murphy, TK; Petersel, DL; Whalen, E, 2010) |
| "This paper reviews recent research on the contribution of the proinflammatory cytokine interleukin-1 (IL- 1) and the purine nucleoside adenosine in mediating behavioral depression and related symptoms of conservation-withdrawal in animal models of both major depression and illness." | 4.86 | Biochemical and anatomical substrates of depression and sickness behavior. ( Furst, SJ; Hanff, TC; Minor, TR, 2010) |
| " Pregabalin seems to provide clinically benefit to patients with fibromyalgia." | 4.85 | [Innovations in ambulatory care]. ( Bodenmann, P; Chapuis, T; Cornuz, J; de Bosset, V; Jaunin-Stalder, N; Marguerat, I; Nanchen, D; Pasche, O, 2009) |
| " The levels of total choline (tCho) and the tCho/N-acetyl aspartate (NAA) ratio were consistently higher in the brains of patients with depression, and that the levels of NAA, glutamate and glutamine (Glx), and gamma-aminobutyric acid (GABA) were lower." | 4.31 | Altered neurometabolite levels in the brains of patients with depression: A systematic analysis of magnetic resonance spectroscopy studies. ( Hu, L; Liu, Y; Lv, F; Ma, L; Pu, J; Shen, Y; Shi, Y; Xie, X; Yang, W; Zhang, H, 2023) |
| "Ketamine can produce rapid-acting antidepressant effects in treatment-resistant patients with depression." | 4.31 | A role of GABA ( Diao, YG; Duan, GF; Hashimoto, K; Ren, ZY; Shen, JC; Tang, XH; Wang, XM; Yang, JJ; Zang, YY; Zhang, GF; Zhou, ZQ, 2023) |
| "In well-established spared nerve injury (SNI)-induced chronic pain-related depression models, the expression of DNMTs and the functional roles and underlying mechanisms of DNMT1 in central amygdala (CeA) GABAergic (gamma-aminobutyric acidergic) neurons were investigated using molecular, pharmacological, electrophysiological, optogenetic, and chemogenetic techniques and behavioral tests." | 4.31 | DNMT1 Mediates Chronic Pain-Related Depression by Inhibiting GABAergic Neuronal Activation in the Central Amygdala. ( Chen, C; Ding, X; Lin, Y; Liu, Q; Wu, Y; Yan, B; Zheng, H; Zhou, C, 2023) |
| "Although escitalopram is known to be an effective drug for adult depression, its disease-modifying efficacy on adolescents remains controversial." | 4.31 | Effects of Escitalopram on the Functional Neural Circuits in an Animal Model of Adolescent Depression. ( Choi, JY; Han, SJ; Kang, KJ; Lee, N; Nam, KR; Oh, SJ, 2023) |
| "The administration of escitalopram had no therapeutic effect on the adolescent depression." | 4.31 | Effects of Escitalopram on the Functional Neural Circuits in an Animal Model of Adolescent Depression. ( Choi, JY; Han, SJ; Kang, KJ; Lee, N; Nam, KR; Oh, SJ, 2023) |
| "We studied the effects of low-dose ozone therapy on the sleep quality of patients with coronary heart disease (CHD) and insomnia by measuring the levels of brain-derived neurotrophic factor (BDNF) and GABA in blood serum." | 4.02 | Low-Dose Ozone Therapy Improves Sleep Quality in Patients with Insomnia and Coronary Heart Disease by Elevating Serum BDNF and GABA. ( Feng, X; Huang, H; Li, Y; Ren, H; Wang, Y; Yu, S, 2021) |
| "Gamma-aminobutyric acid (GABA) and glutamate neurotransmission have been implicated in the pathophysiology of depression and mechanistically linked to ketamine's antidepressant response." | 4.02 | A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration. ( Coombes, BJ; Frye, MA; Geske, JR; Lanza, IR; Morgan, RJ; Port, JD; Singh, B; Voort, JLV, 2021) |
| " Here, we examined whether levels of immunological protein markers changed with depression, age, or the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)." | 3.91 | Depression, GABA, and Age Correlate with Plasma Levels of Inflammatory Markers. ( Bhandage, AK; Birnir, B; Bongiovanni, S; Cunningham, JL; Ekselius, L; Jin, Z; Kamali-Moghaddam, M; Korol, SV; Shen, Q; Syk, M, 2019) |
| "Based on clinical studies regarding the beneficial effect of gabapentin in depression, we aimed to evaluate the antidepressant-like properties of gabapentin in mice and also the participation of nitric oxide (NO)/cyclic guanosine monophosphate pathway in this effect." | 3.83 | Involvement of NO/cGMP pathway in the antidepressant-like effect of gabapentin in mouse forced swimming test. ( Akhlaghipour, G; Ameli, S; Dehpour, A; Haj-Mirzaian, A; Kordjazy, N; Ostadhadi, S, 2016) |
| " This protocol was validated by determining the postmortem cerebrospinal fluid (CSF) glutamic acid (Glu) and γ-aminobutyric acid (GABA) levels of 8 major depressive disorder (MDD) patients, 9 bipolar disorder (BD) patients, and 19 well-matched controls, while also testing the plasma and CSF AA levels of living MDD patients." | 3.83 | A sensitive and practical RP-HPLC-FLD for determination of the low neuroactive amino acid levels in body fluids and its application in depression. ( Bao, AM; Wu, JL; Wu, SH; Yu, SY, 2016) |
| " Based on this, the aim of the present study was to investigate the effect of magnesium on the level of glutamic acid decarboxylase-67kDa (GAD-67) in the different brain areas in the chronic mild stress (CMS) and olfactory bulbectomy (OB) models of depression in rats." | 3.83 | Brain glutamic acid decarboxylase-67kDa alterations induced by magnesium treatment in olfactory bulbectomy and chronic mild stress models in rats. ( Nowak, G; Pochwat, B; Szewczyk, B, 2016) |
| "This investigation indicated that pregabalin is safe and effective for reducing both LBP and mood disturbance in patients with depression." | 3.80 | Outcomes of pregabalin in lumbar-disease patients with depression. ( Ozaki, T; Sugimoto, Y; Takigawa, T; Tanaka, M; Tetsunaga, T, 2014) |
| "Increasing evidence underscores the strong, rapid, and sustained antidepressant properties of ketamine with a good tolerability profile in patients with depression; however, the underlying mechanisms are not fully elucidated." | 3.80 | Downregulation of neuregulin 1-ErbB4 signaling in parvalbumin interneurons in the rat brain may contribute to the antidepressant properties of ketamine. ( Liu, XY; Qiu, LL; Sun, HL; Wang, N; Wang, XM; Yang, C; Yang, JJ; Zhang, GF, 2014) |
| "This study investigated whether the spinal or systemic treatment with the lipid resolution mediators resolvin D1 (RvD1), aspirin-triggered resolvin D1 (AT-RvD1) and resolvin D2 (RvD2) might interfere with behavioral and neurochemical changes in the mouse fibromyalgia-like model induced by reserpine." | 3.80 | Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice. ( Campos, MM; Klein, CP; Leite, CE; Maciel, IS; Souza, AH; Sperotto, ND, 2014) |
| "Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter of the central nervous system (CNS) in mammalian, which involved in several mood disorders such as anxiety, depression and schizophrenia." | 3.80 | [The interaction between gamma-aminobutyric acid and other related neurotransmitters in depression]. ( An, SC; Li, JN; Li, Z, 2014) |
| "Nicotine dependence is maintained by the aversive, depression-like effects of nicotine withdrawal and the rewarding effects of acute nicotine." | 3.77 | Both GABA(B) receptor activation and blockade exacerbated anhedonic aspects of nicotine withdrawal in rats. ( Banerjee, D; Finn, MG; Froestl, W; Guery, S; Kaupmann, K; Markou, A; Paterson, NE; Vlachou, S, 2011) |
| "The aim of this study was to investigate the relationship between plasma glutamate, glutamine and gamma-aminobutyric acid (GABA) levels in female patients with major depression treated with S-citalopram or fluoxetine." | 3.75 | The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. ( Calişkan, M; Gören, MZ; Kaplan, OK; Küçükibrahimoğlu, E; Saygin, MZ; Unsal, C, 2009) |
| "Our findings may suggest that GABA, glutamate and glutamine play a role in depression and that plasma GABA may be used as a biomarker for treatment control." | 3.75 | The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. ( Calişkan, M; Gören, MZ; Kaplan, OK; Küçükibrahimoğlu, E; Saygin, MZ; Unsal, C, 2009) |
| "The theory of depression is dominated by the monoamine hypothesis but there is increasing evidence that beyond monoamines, glutamate (Glu) and gamma-aminobutyric acid (GABA) play an essential role in the pathogenesis of depression." | 3.74 | Elevated spectroscopic glutamate/gamma-amino butyric acid in rats bred for learned helplessness. ( Ende, G; Henn, FA; Mahlstedt, MM; Sartorius, A; Vollmayr, B, 2007) |
| "Although studies have demonstrated the efficacy of the new anti-epileptic on the block, Pregabalin, in the treatment of Generalized Anxiety Disorder and Social Anxiety Disorder, there is no study so far of such efficacy for the treatment of depression." | 3.74 | Pregabalin in the treatment of depression. ( Showraki, M, 2007) |
| " longiflorus (CLE) was investigated for sedative, anticonvulsant and behaviour modifying activity using thiopental sleeping, caffeine induced convulsion and forced swimming depression tests." | 3.71 | Sedative, anticonvulsant and behaviour modifying effects of Centranthus longiflorus ssp. longiflorus: a study of comparison to diazepam. ( Büyükokuroğlu, ME; Demirezer, LO; Güvenalp, Z, 2002) |
| "Considerable evidence implicates the neurotransmitter gamma-aminobutyric acid (GABA) in the biochemical pathophysiology of mood disorders." | 3.70 | GABAA alpha-1 subunit gene not associated with depressive symptomatology in mood disorders. ( Catalano, M; Cusin, C; Di Bella, D; Lattuada, E; Lilli, R; Macciardi, F; Serretti, A; Smeraldi, E, 1998) |
| "The authors measured gamma-aminobutyric acid (GABA) levels in the lumbar CSF of patients with depression, with psychosis, or undergoing evaluation for a neurologic disorder." | 3.66 | GABA levels in CSF of patients with psychiatric disorders. ( Bowers, MB; Gold, BI; Roth, RH; Sweeney, DW, 1980) |
| "Depression is the second leading cause of disability in the world population, for which currently available pharmacological therapies either have poor efficacy or have some adverse effects." | 3.01 | Altered neurotransmission in stress-induced depressive disorders: The underlying role of the amygdala in depression. ( Asim, M; Wang, H; Waris, A, 2023) |
| "Allopregnanolone treatment impacted significantly GABA metabolism, oxidative stress, and some of the mitochondria-related outcomes." | 2.90 | Allopregnanolone Treatment Improves Plasma Metabolomic Profile Associated with GABA Metabolism in Fragile X-Associated Tremor/Ataxia Syndrome: a Pilot Study. ( Carrillo, NR; Giulivi, C; Hagerman, RJ; Napoli, E; Rogawski, M; Schneider, A; Tassone, F; Trivedi, A; Wang, JY, 2019) |
| "The pathophysiology of major depressive disorder (MDD), one of the major causes of worldwide disability, is still largely unclear, despite the increasing data reporting evidence of multiple alterations of different systems." | 2.82 | GABA System in Depression: Impact on Pathophysiology and Psychopharmacology. ( Arone, A; Della Vecchia, A; Marazziti, D; Mucci, F; Piccinni, A, 2022) |
| "Cocaine dependence is a major public health problem with no available robustly effective pharmacotherapy." | 2.79 | Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms. ( Cargile, C; Chopra, MP; Guise, JB; Kosten, TR; Mancino, MJ; McGaugh, J; Oliveto, A; Sanders, N; Thostenson, J; Williams, DK, 2014) |
| "Taking pregabalin for the treatment of neuropathic pain poses an increased risk for developing ED in male patients." | 2.79 | Association between neuropathic pain, pregabalin treatment, and erectile dysfunction. ( Atar, M; Bozkurt, M; Bozkurt, Y; Daggulli, M; Em, S; Gocmez, C; Ozbey, I; Soylemez, H; Yildiz, M, 2014) |
| "Treatment with trazodone significantly improved global fibromyalgia severity, sleep quality, and depression, as well as pain interference with daily activities although without showing a direct effect on bodily pain." | 2.76 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| " Trazodone, flexibly dosed (50-300 mg/day), was administered to 66 fibromyalgia patients during 12 weeks; 41 patients who completed the treatment accepted to receive pregabalin, also flexibly dosed (75-450 mg/day), added to trazodone treatment for an additional 12-week period." | 2.76 | Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. ( Calandre, EP; Molina-Barea, R; Morillas-Arques, P; Rico-Villademoros, F; Rodriguez-Lopez, CM, 2011) |
| "Fibromyalgia is a prevalent and disabling disorder characterized by widespread pain and other symptoms such as insomnia, fatigue or depression." | 2.74 | Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial. ( Alda, M; Andrés, E; del Hoyo, YL; García-Campayo, J; Luciano, JV; Magallón, R; Rodero, B; Serrano-Blanco, A, 2009) |
| "Gabapentin 2400 mg/day was given in case of treatment failure or if imipramine treatment was not possible." | 2.71 | Therapeutic outcome in neuropathic pain: relationship to evidence of nervous system lesion. ( Bach, FW; Jensen, TS; Rasmussen, PV; Sindrup, SH, 2004) |
| " This study examined the single-dose pharmacokinetic profiles of Li in 13 patients receiving placebo and then steady-state gabapentin (mean daily dose: 3,646." | 2.69 | Gabapentin does not alter single-dose lithium pharmacokinetics. ( Corá-Locatelli, G; Dunn, RT; Frye, MA; Grothe, D; Ketter, TA; Kimbrell, TA; Piscitelli, S; Post, RM; Vanderham, E, 1998) |
| "Depression and schizophrenia are burdensome, costly serious and disabling mental disorders." | 2.61 | Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders. ( Pilc, A; Wierońska, JM, 2019) |
| "Efficacy of current treatments for painful diabetic neuropathy is limited to an unpredictable subset of patients, possibly reflecting diversity of pain generator mechanisms, and there is a lack of targeted treatments for individual patients." | 2.58 | The H-Reflex as a Biomarker for Spinal Disinhibition in Painful Diabetic Neuropathy. ( Calcutt, NA; Lee-Kubli, C; Malik, RA; Marshall, AG, 2018) |
| "Irritable bowel syndrome is regarded as the prototypic disorder of the brain-gut-microbiota axis that can be responsive to probiotic therapy." | 2.55 | The Microbiome-Gut-Brain Axis in Health and Disease. ( Cryan, JF; Dinan, TG, 2017) |
| "Stress response and depression have a significant impact on modern society." | 2.47 | Corticotropin-releasing hormone, glutamate, and γ-aminobutyric acid in depression. ( Bao, AM; Gao, SF, 2011) |
| "Trimegestone (TMG) is a novel, 19-norpregnane progestin with potent and selective properties." | 2.44 | Preclinical and clinical properties of trimegestone: a potent and selective progestin. ( Bossemeyer, R; Bouchard, P; Sitruk-Ware, R, 2007) |
| " Overall, pregabalin was well tolerated with no new adverse events emerging that have not been reported with its use in other indications." | 2.44 | Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome. ( Owen, RT, 2007) |
| " This was seen in the 150 mg/day, 300-450 mg/day and 600 mg/day dosing groups." | 2.44 | Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. ( Baldinetti, F; Baldwin, DS; Mandel, F; Stein, DJ, 2008) |
| "The most common risk factor for shingles and its potential sequela, PHN, is advanced age." | 2.42 | Post-herpetic neuralgia case study: optimizing pain control. ( Baron, R, 2004) |
| "The incidence of melanoma is rising rapidly, and the use of this regimen is becoming increasingly common." | 2.41 | Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. ( Everett, JR; Gadd, MA; Greenberg, DB; Haluska, FG; Jonasch, E; Mihm, MA; Ott, M; Ryan, BF; Sober, AJ; Tanabe, KK, 2000) |
| "Depression is a common psychiatric disorder prevalent in 10-15% in general population." | 2.41 | The biology of depression. ( Prakash, HM; Sumant, K, 2000) |
| "Ketamine can produce rapid-acting antidepressant effects in treatment-resistant patients with depression." | 1.91 | A role of GABA ( Diao, YG; Duan, GF; Hashimoto, K; Ren, ZY; Shen, JC; Tang, XH; Wang, XM; Yang, JJ; Zang, YY; Zhang, GF; Zhou, ZQ, 2023) |
| "Depression is a complex neuropsychiatric disease with extensive morbidity." | 1.72 | Therapeutic effect of fecal microbiota transplantation on chronic unpredictable mild stress-induced depression. ( Cai, T; Hu, H; Shi, X; Wang, F; Xiao, SL; Yuan, LZ; Zheng, SP; Zhou, B, 2022) |
| "Stress-induced neuroinflammation is widely regarded as one of the primary causes of depression." | 1.72 | Rice Germ Ameliorated Chronic Unpredictable Mild Stress-Induced Depressive-like Behavior by Reducing Neuroinflammation. ( Batsukh, S; Byun, K; Lee, BJ; Oh, S; Park, CH; Rheu, K; Son, KH, 2022) |
| "Gamma-aminobutyric acid was significantly upregulated in susceptible group but downregulated in resilient group." | 1.62 | Alterations of neurotransmitters and related metabolites in the habenula from CUMS-susceptible and -resilient rats. ( Bai, M; Chen, C; Chen, X; Chen, Z; Cheng, K; He, Y; Lan, T; Li, Y; Tian, Y; Wang, Y; Wu, Z; Xie, P; Yu, H, 2021) |
| "Sensory dysfunctions such as allodynia and hyperalgesia are only part of the symptoms associated with neuropathic pain that extend to memory and affectivity deficits." | 1.62 | 2-Pentadecyl-2-oxazoline ameliorates memory impairment and depression-like behaviour in neuropathic mice: possible role of adrenergic alpha2- and H3 histamine autoreceptors. ( Amodeo, P; Belardo, C; Boccella, S; Calignano, A; Cristiano, C; de Novellis, V; Di Marzo, V; Guida, F; Iannotta, M; Iannotti, FA; Infantino, R; Luongo, L; Maione, S; Marabese, I; Paino, S; Palazzo, E; Ricciardi, F; Vitale, RM, 2021) |
| "Seven patients with treatment-resistant depression enrolled in an open-label, feasibility trial of a single IV 40-min ketamine infusion during a functional MR spectroscopy (fMRS) scan utilizing a novel frequency adjusting MEGA-PRESS sequence." | 1.62 | A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration. ( Coombes, BJ; Frye, MA; Geske, JR; Lanza, IR; Morgan, RJ; Port, JD; Singh, B; Voort, JLV, 2021) |
| "Both Major Depressive Disorder (MDD) and Primary Insomnia (PI) have been linked to deficiencies in cortical γ-aminobutyric acid (GABA) and glutamate (Glu) thus suggesting a shared neurobiological link between these two conditions." | 1.56 | ( Baer, L; Benson, KL; Bottary, R; Eric Jensen, J; Gonenc, A; Schoerning, L; Winkelman, JW, 2020) |
| "The extent to which comorbid insomnia contributes to GABAergic or glutamatergic deficiencies in MDD remains unclear." | 1.56 | ( Baer, L; Benson, KL; Bottary, R; Eric Jensen, J; Gonenc, A; Schoerning, L; Winkelman, JW, 2020) |
| "Depression is one of the most common associated diseases, which aggravates psoriatic skin lesions and affects the life quality of patients." | 1.56 | Depressive-like behaviors in mice with Imiquimod-induced psoriasis. ( Di, T; Guo, J; Guo, X; Li, P; Liu, Y; Meng, Y; Qi, C; Wang, Y; Zhang, L; Zhao, J, 2020) |
| "Psoriasis is not only a chronic inflammatory skin disease but also a psychosomatic disorder." | 1.56 | Depressive-like behaviors in mice with Imiquimod-induced psoriasis. ( Di, T; Guo, J; Guo, X; Li, P; Liu, Y; Meng, Y; Qi, C; Wang, Y; Zhang, L; Zhao, J, 2020) |
| "Depression affects approximately 5% of elderly people and its etiology might be related to chronic stress exposure during neurodevelopmental periods." | 1.51 | Adolescent stress increases depression-like behaviors and alters the excitatory-inhibitory balance in aged mice. ( Li, JT; Liu, X; Ma, YN; Si, TM; Su, YA; Sun, YX; Wang, H; Wang, HL, 2019) |
| " In this study, we evaluated whether social isolation in the prepubertal period and chronic use of high-fat diet (HFD) may induce depressive-like behavior in male adult rats." | 1.48 | Impact of High-Fat Diet and Early Stress on Depressive-Like Behavior and Hippocampal Plasticity in Adult Male Rats. ( Arcego, DM; Berlitz, C; Dalmaz, C; do Couto Nicola, F; Dos Santos Garcia, E; Gaelzer, MM; Hoppe, JB; Klein, CP; Krolow, R; Lampert, C; Lazzaretti, C; Toniazzo, AP, 2018) |
| "It is known that depression is a psychiatric disorder with a high prevalence worldwide, including high rates among adolescents." | 1.48 | Impact of High-Fat Diet and Early Stress on Depressive-Like Behavior and Hippocampal Plasticity in Adult Male Rats. ( Arcego, DM; Berlitz, C; Dalmaz, C; do Couto Nicola, F; Dos Santos Garcia, E; Gaelzer, MM; Hoppe, JB; Klein, CP; Krolow, R; Lampert, C; Lazzaretti, C; Toniazzo, AP, 2018) |
| " We investigated the effect of long-term administration of ERI in three different doses on behavioral changes, hippocampal and prefrontal cortex (PFC) neurogenesis, and γ-aminobutyric acid (GABA)/glutamate balance in male Wistar rats exposed to chronic restraint stress (CRS)." | 1.48 | Behavioral effects of toll-like receptor-4 antagonist 'eritoran' in an experimental model of depression: role of prefrontal and hippocampal neurogenesis and γ-aminobutyric acid/glutamate balance. ( Aboul-Fotouh, S; Asaad, T; Ghanem, MH; Habib, M; Kassim, SK, 2018) |
| "Depression is the disease of the modern era." | 1.48 | Behavioral effects of toll-like receptor-4 antagonist 'eritoran' in an experimental model of depression: role of prefrontal and hippocampal neurogenesis and γ-aminobutyric acid/glutamate balance. ( Aboul-Fotouh, S; Asaad, T; Ghanem, MH; Habib, M; Kassim, SK, 2018) |
| "Studies on migraine and depression have revealed correlations with hormonal fluctuations in females as well as aberrant levels of some key neurotransmitters such as Gamma-Aminobutyric Acid (GABA) and inflammatory neuropeptides like Calcitonin Gene-Related Peptide (CGRP)." | 1.48 | A new theory on GABA and Calcitonin Gene-Related Peptide involvement in Mal de Debarquement Syndrome predisposition factors and pathophysiology. ( Browne, CJ; Jacquemyn, Y; Mucci, V; Van de Heyning, PH; Van Ombergen, A, 2018) |
| "The analysis of the case of vulvodynia coexisting with depression." | 1.46 | Vulvodynia and depression - a case study. ( Derewianka-Polak, M; Dziwota, EA; Gerhant, A; Olajossy, M; Perzyńska-Starkiewicz, A, 2017) |
| "Pretreatment with spermine, considerably, reversed the PTZ induced alterations." | 1.46 | Protective effect of spermine against pentylenetetrazole kindling epilepsy induced comorbidities in mice. ( Kumar, M; Kumar, P, 2017) |
| "Spermine is an endogenous polyamine; possesses anti-oxidant property and has ability to modulate ion channels and NO synthase activity." | 1.46 | Protective effect of spermine against pentylenetetrazole kindling epilepsy induced comorbidities in mice. ( Kumar, M; Kumar, P, 2017) |
| "Depression was modelled by the olfactory bulbectomy (OBX) in Wistar male rats." | 1.42 | Reward related neurotransmitter changes in a model of depression: An in vivo microdialysis study. ( Amchova, P; Babinska, Z; Havlickova, T; Jerabek, P; Kacer, P; Ruda-Kucerova, J; Sulcova, A; Sustkova-Fiserova, M; Syslova, K, 2015) |
| "Depression is a complex neuropsychiatric syndrome that is often very severe and life threatening." | 1.40 | Dysfunctional glutamatergic and γ-aminobutyric acidergic activities in prefrontal cortex of mice in social defeat model of depression. ( Bagga, P; Chakravarty, S; Khandelwal, N; Kumar, A; Maitra, S; Noronha, JM; Patel, AB; Veeraiah, P, 2014) |
| " Noteworthy, the repeated administration of AT-RvD1 and RvD2 also prevented the depressive-like behavior in reserpine-treated animals, according to assessment of immobility time, although the chronic administration of pregabalin failed to affect this parameter." | 1.40 | Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice. ( Campos, MM; Klein, CP; Leite, CE; Maciel, IS; Souza, AH; Sperotto, ND, 2014) |
| "Intracranial stab wounds are low-velocity, penetrating injuries to the brain and fatality and outcome significantly depend on route, depth and location of cranial penetration." | 1.39 | Self-inflicted trans-oral intracranial stab wound. ( Han, ZA; Kim, JH; Kim, SW, 2013) |
| "Major depression is a mental disorder often preceded by exposure to chronic stress or stressful life events." | 1.39 | Social vs. environmental stress models of depression from a behavioural and neurochemical approach. ( Elizalde, N; García-García, AL; Tordera, RM; Venzala, E, 2013) |
| "A well-validated animal model of treatment resistant depression (congenital learned helpless rats = cLH) was investigated by hippocampal in vivo ¹H MRS with and without a 1-week course of electroconvulsive shocks (ECS), an animal model of ECT, and compared to wild type (WT) animals, while saline and clomipramine injections served as additional controls." | 1.38 | Increase of hippocampal glutamate after electroconvulsive treatment: a quantitative proton MR spectroscopy study at 9.4 T in an animal model of depression. ( Biedermann, S; Ende, G; Gass, P; Hoyer, C; Sartorius, A; Vollmayr, B; Weber-Fahr, W; Zheng, L, 2012) |
| "Corticosterone induced an increase glutamate and a decrease in GABA release in hippocampal slices, which was reversed by venlafaxine." | 1.38 | Long lasting effects of early-life stress on glutamatergic/GABAergic circuitry in the rat hippocampus. ( Horrillo, I; Martisova, E; Meana, JJ; Ortega, JE; Ramírez, MJ; Solas, M; Tordera, RM, 2012) |
| "Depression, epilepsy, post traumatic stress disorder (PTSD), and chronic pain exemplify medical conditions that are exacerbated by stress, have low heart rate variability (HRV) and low GABAergic activity, respond to pharmacologic agents that increase activity of the GABA system, and show symptom improvement in response to yoga-based interventions." | 1.38 | Effects of yoga on the autonomic nervous system, gamma-aminobutyric-acid, and allostasis in epilepsy, depression, and post-traumatic stress disorder. ( Brown, RP; Ciraulo, DA; Gerbarg, PL; Saper, RB; Streeter, CC, 2012) |
| " In a long-term test, the antidepressant-like effect of MFP was better than that of GABA at the same dosage (2." | 1.37 | Antidepressant effect of GABA-rich monascus-fermented product on forced swimming rat model. ( Chuang, CY; Lo, YH; Pan, TM; Shi, YC; You, HP, 2011) |
| "Stress-induced depression is a kind of functional and structural disability of the brain and involves many neurotransmitters and regions of the brain." | 1.37 | [Rat orbital frontal (orbital frontal cortex, OFC) GABA B receptor mechanisms in stress and depression]. ( An, SC; Gu, CY, 2011) |
| "Tobacco smoking and depression are strongly associated, but the possible effects of SHS have not been evaluated." | 1.36 | Secondhand smoke exposure and depressive symptoms. ( Arheart, KL; Bandiera, FC; Caban-Martinez, AJ; Davila, EP; Dietz, NA; Fleming, LE; Leblanc, WG; Lee, DJ; Lewis, JE; McCollister, K; Serdar, B, 2010) |
| "Anxiety and depression are often also present." | 1.35 | Fibromyalgia: poorly understood; treatments are disappointing. ( , 2009) |
| "(1) Fibromyalgia is characterised by a range of symptoms that include muscle pain, fatigue and sleep disorders." | 1.35 | Fibromyalgia: poorly understood; treatments are disappointing. ( , 2009) |
| "Tolerance, dependence, and adverse effects on cognitive functions are well known consequences of long-term use of benzodiazepines (BDZ), especially at high doses; this raises thorny therapeutic problems in their discontinuation." | 1.35 | Pregabalin in the discontinuation of long-term benzodiazepine use: a case-series. ( Karakatsanis, NA; Karapoulios, E; Konstantakopoulos, G; Kouzoupis, AV; Masdrakis, VG; Oulis, P; Soldatos, CR, 2008) |
| "The theory of depression is dominated by the monoamine hypothesis but there is increasing evidence that beyond monoamines, glutamate (Glu) and gamma-aminobutyric acid (GABA) play an essential role in the pathogenesis of depression." | 1.34 | Elevated spectroscopic glutamate/gamma-amino butyric acid in rats bred for learned helplessness. ( Ende, G; Henn, FA; Mahlstedt, MM; Sartorius, A; Vollmayr, B, 2007) |
| "Symptoms consistent with bruxism are a common chief complaint in dental practice." | 1.30 | Antidepressant-induced bruxism successfully treated with gabapentin. ( Brown, ES; Hong, SC, 1999) |
| "A case of bruxism, anxiety, insomnia and tremor is reported in a man with bipolar disorder that developed a few days after he initiated venlafaxine therapy for depression." | 1.30 | Antidepressant-induced bruxism successfully treated with gabapentin. ( Brown, ES; Hong, SC, 1999) |
| "Lethargy and mental depression are early symptoms, followed by mild parkinsonism and progressive weight loss." | 1.26 | Familial fatal Parkinsonism with alveolar hypoventilation and mental depression. ( Ahmad, D; Barnett, HJ; Bratty, P; Hahn, A; Lloyd, KG; McGeer, EG; Perry, TL; Purdy, A, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (9.70) | 18.7374 |
| 1990's | 11 (4.64) | 18.2507 |
| 2000's | 49 (20.68) | 29.6817 |
| 2010's | 102 (43.04) | 24.3611 |
| 2020's | 52 (21.94) | 2.80 |
| Authors | Studies |
|---|---|
| Pankowska, A | 1 |
| Chudzik, A | 1 |
| Słowik, T | 1 |
| Łazorczyk, A | 1 |
| Kochalska, K | 1 |
| Andres-Mach, M | 1 |
| Lam, WW | 1 |
| Pietura, R | 1 |
| Rola, R | 1 |
| Stanisz, GJ | 1 |
| Orzyłowska, A | 1 |
| Della Vecchia, A | 1 |
| Arone, A | 1 |
| Piccinni, A | 1 |
| Mucci, F | 1 |
| Marazziti, D | 1 |
| Ngoupaye, GT | 1 |
| Mokgokong, M | 1 |
| Madlala, T | 1 |
| Mabandla, MV | 1 |
| Singh, B | 2 |
| Port, JD | 2 |
| Pazdernik, V | 1 |
| Coombes, BJ | 2 |
| Vande Voort, JL | 1 |
| Frye, MA | 3 |
| Qi, G | 1 |
| Zhang, P | 2 |
| Li, T | 1 |
| Li, M | 2 |
| Zhang, Q | 1 |
| He, F | 1 |
| Zhang, L | 5 |
| Cai, H | 1 |
| Lv, X | 1 |
| Qiao, H | 1 |
| Chen, X | 3 |
| Ming, J | 1 |
| Tian, B | 1 |
| Xue, X | 2 |
| Pan, J | 2 |
| Zhang, H | 4 |
| Lu, Y | 3 |
| Mao, Q | 1 |
| Ma, K | 2 |
| Mayneris-Perxachs, J | 1 |
| Castells-Nobau, A | 1 |
| Arnoriaga-Rodríguez, M | 1 |
| Martin, M | 1 |
| de la Vega-Correa, L | 1 |
| Zapata, C | 1 |
| Burokas, A | 1 |
| Blasco, G | 1 |
| Coll, C | 1 |
| Escrichs, A | 1 |
| Biarnés, C | 1 |
| Moreno-Navarrete, JM | 1 |
| Puig, J | 1 |
| Garre-Olmo, J | 1 |
| Ramos, R | 1 |
| Pedraza, S | 1 |
| Brugada, R | 1 |
| Vilanova, JC | 1 |
| Serena, J | 1 |
| Gich, J | 1 |
| Ramió-Torrentà, L | 1 |
| Pérez-Brocal, V | 1 |
| Moya, A | 1 |
| Pamplona, R | 1 |
| Sol, J | 1 |
| Jové, M | 1 |
| Ricart, W | 1 |
| Portero-Otin, M | 1 |
| Deco, G | 1 |
| Maldonado, R | 1 |
| Fernández-Real, JM | 1 |
| Gonsalves, MA | 1 |
| White, TL | 1 |
| Barredo, J | 1 |
| Fukuda, AM | 1 |
| Joyce, HE | 1 |
| Harris, AD | 1 |
| Carpenter, LL | 2 |
| Cai, T | 1 |
| Zheng, SP | 1 |
| Shi, X | 1 |
| Yuan, LZ | 1 |
| Hu, H | 1 |
| Zhou, B | 1 |
| Xiao, SL | 1 |
| Wang, F | 1 |
| Guath, M | 1 |
| Kleberg, JL | 1 |
| Weis, J | 1 |
| Widegren, E | 1 |
| Frick, M | 1 |
| Möller, S | 1 |
| Klevebrant, L | 1 |
| Karlsson, B | 1 |
| Fällmar, D | 1 |
| Mårtensson, J | 1 |
| Pine, DS | 1 |
| Brocki, K | 1 |
| Gingnell, M | 1 |
| Frick, A | 1 |
| Biermann, L | 1 |
| Wunram, HL | 1 |
| Pokorny, L | 1 |
| Breitinger, E | 1 |
| Großheinrich, N | 1 |
| Jarczok, TA | 1 |
| Bender, S | 1 |
| Tabassum, S | 1 |
| Misrani, A | 1 |
| Huo, Q | 1 |
| Ahmed, A | 1 |
| Long, C | 1 |
| Yang, L | 1 |
| Chen, Z | 2 |
| Gu, J | 1 |
| Lin, S | 1 |
| Xu, Z | 1 |
| Xu, H | 1 |
| Zhao, J | 3 |
| Feng, P | 1 |
| Tao, Y | 1 |
| Chen, S | 1 |
| Wang, P | 3 |
| Wang, YS | 1 |
| Qiu, TY | 1 |
| Fu, Q | 1 |
| Xiong, SQ | 1 |
| Wang, ZZ | 1 |
| Lu, MF | 1 |
| Yang, JH | 1 |
| Hu, ZZ | 1 |
| Jiang, C | 1 |
| Wang, H | 3 |
| Qi, J | 1 |
| Li, J | 1 |
| He, Q | 1 |
| Wang, C | 2 |
| Gao, Y | 5 |
| Chi, X | 1 |
| Wu, J | 1 |
| Shi, H | 1 |
| Wang, Y | 8 |
| Zhang, Z | 1 |
| Xie, X | 2 |
| Shi, Y | 2 |
| Ma, L | 2 |
| Yang, W | 2 |
| Pu, J | 2 |
| Shen, Y | 2 |
| Liu, Y | 3 |
| Lv, F | 2 |
| Hu, L | 2 |
| Batsukh, S | 1 |
| Oh, S | 1 |
| Rheu, K | 1 |
| Lee, BJ | 1 |
| Park, CH | 1 |
| Son, KH | 1 |
| Byun, K | 1 |
| Tang, XH | 1 |
| Diao, YG | 1 |
| Ren, ZY | 1 |
| Zang, YY | 1 |
| Zhang, GF | 2 |
| Wang, XM | 2 |
| Duan, GF | 1 |
| Shen, JC | 1 |
| Hashimoto, K | 1 |
| Zhou, ZQ | 1 |
| Yang, JJ | 2 |
| Rupprecht, R | 1 |
| Pradhan, AK | 1 |
| Kufner, M | 1 |
| Brunner, LM | 1 |
| Nothdurfter, C | 1 |
| Wein, S | 1 |
| Schwarzbach, J | 1 |
| Puig, X | 1 |
| Rupprecht, C | 1 |
| Rammes, G | 1 |
| Marcinkowska, M | 1 |
| Mordyl, B | 1 |
| Fajkis-Zajaczkowska, N | 1 |
| Siwek, A | 1 |
| Karcz, T | 1 |
| Gawalska, A | 1 |
| Bucki, A | 1 |
| Żmudzki, P | 1 |
| Partyka, A | 1 |
| Jastrzębska-Więsek, M | 1 |
| Pomierny, B | 1 |
| Walczak, M | 1 |
| Smolik, M | 1 |
| Pytka, K | 1 |
| Mika, K | 1 |
| Kotańska, M | 1 |
| Kolaczkowski, M | 1 |
| Johnston, JN | 1 |
| Kadriu, B | 1 |
| Allen, J | 1 |
| Gilbert, JR | 1 |
| Henter, ID | 1 |
| Zarate, CA | 1 |
| Asim, M | 1 |
| Waris, A | 1 |
| Ding, X | 1 |
| Lin, Y | 1 |
| Chen, C | 2 |
| Yan, B | 1 |
| Liu, Q | 1 |
| Zheng, H | 1 |
| Wu, Y | 1 |
| Zhou, C | 1 |
| Oh, SJ | 1 |
| Lee, N | 1 |
| Nam, KR | 1 |
| Kang, KJ | 1 |
| Han, SJ | 1 |
| Choi, JY | 1 |
| Sun, X | 1 |
| Wang, Z | 2 |
| Li, Y | 3 |
| Wang, J | 3 |
| Liu, G | 1 |
| Xu, K | 1 |
| Ai, K | 1 |
| Huang, W | 1 |
| Zhang, J | 1 |
| Luscher, B | 2 |
| Maguire, JL | 1 |
| Rudolph, U | 1 |
| Sibille, E | 3 |
| Uchida, T | 1 |
| Sugiura, Y | 1 |
| Sugiyama, E | 1 |
| Maeda, R | 1 |
| Tanaka, KF | 1 |
| Suematsu, M | 1 |
| Mimura, M | 1 |
| Uchida, H | 1 |
| Schumacher, A | 1 |
| Haegele, M | 1 |
| Spyth, J | 1 |
| Moser, A | 1 |
| Patterson, E | 1 |
| Ryan, PM | 1 |
| Wiley, N | 1 |
| Carafa, I | 1 |
| Sherwin, E | 1 |
| Moloney, G | 1 |
| Franciosi, E | 1 |
| Mandal, R | 1 |
| Wishart, DS | 1 |
| Tuohy, K | 1 |
| Ross, RP | 1 |
| Cryan, JF | 2 |
| Dinan, TG | 2 |
| Stanton, C | 1 |
| Ghosal, S | 1 |
| Duman, CH | 1 |
| Liu, RJ | 1 |
| Wu, M | 1 |
| Terwilliger, R | 1 |
| Girgenti, MJ | 1 |
| Wohleb, E | 1 |
| Fogaca, MV | 1 |
| Teichman, EM | 1 |
| Hare, B | 1 |
| Duman, RS | 1 |
| Bhandage, AK | 1 |
| Cunningham, JL | 1 |
| Jin, Z | 1 |
| Shen, Q | 1 |
| Bongiovanni, S | 1 |
| Korol, SV | 1 |
| Syk, M | 1 |
| Kamali-Moghaddam, M | 1 |
| Ekselius, L | 1 |
| Birnir, B | 1 |
| Draganov, M | 1 |
| Vives-Gilabert, Y | 1 |
| de Diego-Adeliño, J | 1 |
| Vicent-Gil, M | 1 |
| Puigdemont, D | 1 |
| Portella, MJ | 1 |
| Matiushenko, V | 1 |
| Kutasevych, Y | 1 |
| Jafferany, M | 1 |
| Prévot, T | 1 |
| Benson, KL | 1 |
| Bottary, R | 1 |
| Schoerning, L | 1 |
| Baer, L | 1 |
| Gonenc, A | 1 |
| Eric Jensen, J | 1 |
| Winkelman, JW | 1 |
| Srivastava, I | 1 |
| Vazquez-Juarez, E | 1 |
| Henning, L | 1 |
| Gómez-Galán, M | 1 |
| Lindskog, M | 1 |
| Duranti, S | 1 |
| Ruiz, L | 1 |
| Lugli, GA | 1 |
| Tames, H | 1 |
| Milani, C | 1 |
| Mancabelli, L | 1 |
| Mancino, W | 1 |
| Longhi, G | 1 |
| Carnevali, L | 1 |
| Sgoifo, A | 1 |
| Margolles, A | 1 |
| Ventura, M | 1 |
| Ruas-Madiedo, P | 1 |
| Turroni, F | 1 |
| Lyu, S | 1 |
| Guo, Y | 2 |
| Tang, G | 2 |
| Li, R | 1 |
| Yang, J | 1 |
| Gao, S | 1 |
| Ma, B | 1 |
| Liu, J | 3 |
| Sbrini, G | 1 |
| Brivio, P | 1 |
| Bosch, K | 1 |
| Homberg, JR | 1 |
| Calabrese, F | 1 |
| Wu, Z | 2 |
| Pan, D | 1 |
| Zeng, X | 1 |
| Zhao, G | 1 |
| Guo, J | 1 |
| Guo, X | 2 |
| Meng, Y | 1 |
| Qi, C | 1 |
| Di, T | 1 |
| Li, P | 4 |
| Tian, Y | 1 |
| He, Y | 2 |
| Lan, T | 1 |
| Bai, M | 1 |
| Yu, H | 1 |
| Cheng, K | 1 |
| Xie, P | 1 |
| Boccella, S | 1 |
| Guida, F | 1 |
| Iannotta, M | 1 |
| Iannotti, FA | 1 |
| Infantino, R | 1 |
| Ricciardi, F | 1 |
| Cristiano, C | 1 |
| Vitale, RM | 1 |
| Amodeo, P | 1 |
| Marabese, I | 1 |
| Belardo, C | 1 |
| de Novellis, V | 1 |
| Paino, S | 1 |
| Palazzo, E | 1 |
| Calignano, A | 1 |
| Di Marzo, V | 1 |
| Maione, S | 1 |
| Luongo, L | 1 |
| Arsenijevic, N | 1 |
| Selakovic, D | 1 |
| Katanic Stankovic, JS | 1 |
| Mihailovic, V | 1 |
| Mitrovic, S | 1 |
| Milenkovic, J | 1 |
| Milanovic, P | 1 |
| Vasovic, M | 1 |
| Markovic, SD | 1 |
| Zivanovic, M | 1 |
| Grujic, J | 1 |
| Jovicic, N | 1 |
| Rosic, G | 1 |
| Feng, X | 1 |
| Ren, H | 1 |
| Huang, H | 1 |
| Yu, S | 1 |
| Xia, G | 1 |
| Han, Y | 1 |
| Meng, F | 1 |
| Srisai, D | 1 |
| Farias, M | 1 |
| Dang, M | 1 |
| Palmiter, RD | 1 |
| Xu, Y | 1 |
| Wu, Q | 1 |
| Cao, Q | 1 |
| Hao, Y | 1 |
| Zhao, F | 1 |
| Fu, R | 1 |
| Yu, Y | 1 |
| Niu, R | 1 |
| Bian, S | 1 |
| Sun, Z | 1 |
| Cao, G | 1 |
| Meng, G | 1 |
| Zhu, L | 1 |
| Zhu, J | 1 |
| Dong, N | 1 |
| Zhou, X | 1 |
| Zhang, S | 2 |
| Zhang, Y | 1 |
| Song, XM | 1 |
| Hu, XW | 1 |
| Li, Z | 2 |
| Ju, X | 1 |
| Liu, DY | 1 |
| Wang, QN | 1 |
| Xue, C | 1 |
| Cai, YC | 1 |
| Bai, R | 1 |
| Tan, ZL | 1 |
| Northoff, G | 1 |
| Voort, JLV | 1 |
| Geske, JR | 1 |
| Lanza, IR | 1 |
| Morgan, RJ | 1 |
| Ironside, M | 1 |
| Moser, AD | 1 |
| Holsen, LM | 1 |
| Zuo, CS | 1 |
| Du, F | 1 |
| Perlo, S | 1 |
| Richards, CE | 1 |
| Duda, JM | 1 |
| Nickerson, LD | 1 |
| Null, KE | 1 |
| Nascimento, N | 1 |
| Crowley, DJ | 1 |
| Misra, M | 1 |
| Goldstein, JM | 1 |
| Pizzagalli, DA | 1 |
| Lin, M | 1 |
| Li, H | 4 |
| Zhao, Y | 3 |
| Cai, E | 3 |
| Zhu, H | 1 |
| Liu, S | 1 |
| Yang, H | 1 |
| Wang, R | 1 |
| Arcego, DM | 1 |
| Toniazzo, AP | 1 |
| Krolow, R | 1 |
| Lampert, C | 1 |
| Berlitz, C | 1 |
| Dos Santos Garcia, E | 1 |
| do Couto Nicola, F | 1 |
| Hoppe, JB | 1 |
| Gaelzer, MM | 1 |
| Klein, CP | 2 |
| Lazzaretti, C | 1 |
| Dalmaz, C | 1 |
| Daglia, M | 2 |
| Di Lorenzo, A | 2 |
| Nabavi, SF | 2 |
| Sureda, A | 2 |
| Khanjani, S | 2 |
| Moghaddam, AH | 2 |
| Braidy, N | 1 |
| Nabavi, SM | 2 |
| Lukkes, JL | 1 |
| Meda, S | 1 |
| Thompson, BS | 2 |
| Freund, N | 2 |
| Andersen, SL | 2 |
| Qiuxia, Z | 1 |
| Xinlong, M | 1 |
| Yilong, Y | 1 |
| Hui, Z | 1 |
| Yali, W | 1 |
| Xiaoquan, Y | 1 |
| Lei, W | 1 |
| Jiahui, C | 1 |
| Haiyan, Z | 1 |
| Wu, X | 1 |
| Balesar, R | 1 |
| Lu, J | 1 |
| Farajnia, S | 1 |
| Zhu, Q | 1 |
| Huang, M | 2 |
| Bao, AM | 3 |
| Swaab, DF | 2 |
| Fee, C | 1 |
| Banasr, M | 1 |
| Teng, J | 1 |
| Zhou, W | 1 |
| Zeng, Z | 1 |
| Zhao, W | 1 |
| Huang, Y | 1 |
| Zhang, X | 1 |
| Xiao, J | 1 |
| Song, M | 1 |
| Li, F | 1 |
| Liu, X | 5 |
| Anwar, A | 1 |
| Zhao, H | 1 |
| Ho, YC | 1 |
| Lin, TB | 1 |
| Hsieh, MC | 1 |
| Lai, CY | 1 |
| Chou, D | 1 |
| Chau, YP | 1 |
| Chen, GD | 1 |
| Peng, HY | 1 |
| Gabbay, V | 1 |
| Bradley, KA | 1 |
| Mao, X | 1 |
| Ostrover, R | 1 |
| Kang, G | 1 |
| Shungu, DC | 1 |
| Flores-Ramos, M | 1 |
| Salinas, M | 1 |
| Carvajal-Lohr, A | 1 |
| Rodríguez-Bores, L | 1 |
| Hoggard, M | 1 |
| Nocera, A | 1 |
| Biswas, K | 1 |
| Taylor, MW | 1 |
| Douglas, RG | 1 |
| Bleier, BS | 1 |
| Gerhant, A | 1 |
| Dziwota, EA | 1 |
| Perzyńska-Starkiewicz, A | 1 |
| Derewianka-Polak, M | 1 |
| Olajossy, M | 1 |
| Lee-Kubli, C | 1 |
| Marshall, AG | 1 |
| Malik, RA | 1 |
| Calcutt, NA | 1 |
| Bian, X | 1 |
| Aboul-Fotouh, S | 1 |
| Habib, M | 1 |
| Asaad, T | 1 |
| Kassim, SK | 1 |
| Ghanem, MH | 1 |
| Verwer, RWH | 1 |
| Gao, SF | 2 |
| Qi, XR | 1 |
| Lucassen, PJ | 1 |
| Kessels, HW | 1 |
| Wierońska, JM | 1 |
| Pilc, A | 2 |
| Napoli, E | 1 |
| Schneider, A | 1 |
| Wang, JY | 1 |
| Trivedi, A | 1 |
| Carrillo, NR | 1 |
| Tassone, F | 1 |
| Rogawski, M | 1 |
| Hagerman, RJ | 1 |
| Giulivi, C | 1 |
| Mucci, V | 1 |
| Jacquemyn, Y | 1 |
| Van Ombergen, A | 1 |
| Van de Heyning, PH | 1 |
| Browne, CJ | 1 |
| Fu, T | 1 |
| Strandwitz, P | 1 |
| Kim, KH | 1 |
| Terekhova, D | 1 |
| Liu, JK | 1 |
| Sharma, A | 1 |
| Levering, J | 1 |
| McDonald, D | 1 |
| Dietrich, D | 1 |
| Ramadhar, TR | 1 |
| Lekbua, A | 1 |
| Mroue, N | 1 |
| Liston, C | 1 |
| Stewart, EJ | 1 |
| Dubin, MJ | 1 |
| Zengler, K | 1 |
| Knight, R | 1 |
| Gilbert, JA | 1 |
| Clardy, J | 1 |
| Lewis, K | 1 |
| Galyamina, AG | 1 |
| Kovalenko, IL | 1 |
| Smagin, DA | 1 |
| Kudryavtseva, NN | 1 |
| Zhang, C | 2 |
| Kalueff, AV | 1 |
| Song, C | 1 |
| Gilbert, N | 1 |
| Wang, HL | 1 |
| Sun, YX | 1 |
| Ma, YN | 1 |
| Su, YA | 1 |
| Li, JT | 1 |
| Si, TM | 1 |
| Kumar, K | 1 |
| Sharma, S | 1 |
| Kumar, P | 2 |
| Deshmukh, R | 1 |
| Kim, SW | 1 |
| Kim, JH | 1 |
| Han, ZA | 1 |
| Marchiori, ÉC | 1 |
| Barber, JS | 1 |
| Williams, WB | 1 |
| Bui, PQ | 1 |
| O'Ryan, FS | 1 |
| Mah, L | 1 |
| Hart, M | 1 |
| Maciel, IS | 2 |
| Silva, RB | 1 |
| Morrone, FB | 1 |
| Calixto, JB | 1 |
| Campos, MM | 2 |
| Veeraiah, P | 1 |
| Noronha, JM | 1 |
| Maitra, S | 1 |
| Bagga, P | 1 |
| Khandelwal, N | 1 |
| Chakravarty, S | 1 |
| Kumar, A | 1 |
| Patel, AB | 1 |
| Perrine, SA | 1 |
| Ghoddoussi, F | 1 |
| Michaels, MS | 1 |
| Sheikh, IS | 1 |
| McKelvey, G | 1 |
| Galloway, MP | 1 |
| Tetsunaga, T | 2 |
| Tanaka, M | 1 |
| Sugimoto, Y | 1 |
| Takigawa, T | 1 |
| Ozaki, T | 1 |
| Mancino, MJ | 1 |
| McGaugh, J | 1 |
| Chopra, MP | 1 |
| Guise, JB | 1 |
| Cargile, C | 1 |
| Williams, DK | 1 |
| Thostenson, J | 1 |
| Kosten, TR | 1 |
| Sanders, N | 1 |
| Oliveto, A | 1 |
| El Zahaf, NA | 1 |
| Salem Elhwuegi, A | 1 |
| Bozkurt, M | 1 |
| Gocmez, C | 1 |
| Soylemez, H | 1 |
| Daggulli, M | 1 |
| Em, S | 1 |
| Yildiz, M | 1 |
| Atar, M | 1 |
| Bozkurt, Y | 1 |
| Ozbey, I | 1 |
| Wang, N | 1 |
| Liu, XY | 1 |
| Sun, HL | 1 |
| Qiu, LL | 1 |
| Yang, C | 1 |
| Lu, B | 1 |
| Nagappan, G | 1 |
| Kim, SY | 1 |
| Lee, DW | 1 |
| -Kim, H | 1 |
| Bang, E | 1 |
| Chae, JH | 1 |
| Choe, BY | 1 |
| Sperotto, ND | 1 |
| Leite, CE | 1 |
| Souza, AH | 1 |
| Mehta, S | 1 |
| McIntyre, A | 1 |
| Dijkers, M | 1 |
| Loh, E | 1 |
| Teasell, RW | 1 |
| Lonstein, JS | 1 |
| Maguire, J | 1 |
| Meinlschmidt, G | 1 |
| Neumann, ID | 1 |
| Kilic, FS | 1 |
| Ismailoglu, S | 1 |
| Kaygisiz, B | 1 |
| Oner, S | 1 |
| Ren, Z | 1 |
| Sahir, N | 1 |
| Murakami, S | 1 |
| Luellen, BA | 1 |
| Earnheart, JC | 1 |
| Lal, R | 1 |
| Kim, JY | 1 |
| Song, H | 1 |
| Stratton, MS | 1 |
| Staros, M | 1 |
| Budefeld, T | 1 |
| Searcy, BT | 1 |
| Nash, C | 1 |
| Eitel, C | 1 |
| Carbone, D | 1 |
| Handa, RJ | 1 |
| Majdic, G | 1 |
| Tobet, SA | 1 |
| An, SC | 2 |
| Li, JN | 1 |
| Shabel, SJ | 1 |
| Proulx, CD | 1 |
| Piriz, J | 1 |
| Malinow, R | 1 |
| Gao, X | 1 |
| Sun, P | 1 |
| Qiao, M | 1 |
| Wei, S | 1 |
| Xue, L | 1 |
| Baniasadi, M | 1 |
| Hosseini, G | 1 |
| Fayyazi Bordbar, MR | 1 |
| Rezaei Ardani, A | 1 |
| Mostafavi Toroghi, H | 1 |
| Nieto-Gonzalez, JL | 2 |
| Holm, MM | 2 |
| Vardya, I | 2 |
| Christensen, T | 1 |
| Wiborg, O | 2 |
| Jensen, K | 2 |
| Evrensel, A | 1 |
| Ünsalver, BÖ | 1 |
| Yasin Wayhs, CA | 1 |
| Tannhauser Barros, HM | 1 |
| Vargas, CR | 1 |
| Ruda-Kucerova, J | 1 |
| Amchova, P | 1 |
| Havlickova, T | 1 |
| Jerabek, P | 1 |
| Babinska, Z | 1 |
| Kacer, P | 1 |
| Syslova, K | 1 |
| Sulcova, A | 1 |
| Sustkova-Fiserova, M | 1 |
| Lubelski, D | 1 |
| Thompson, NR | 1 |
| Agrawal, B | 1 |
| Abdullah, KG | 1 |
| Alvin, MD | 1 |
| Khalaf, T | 1 |
| Mazanec, DJ | 1 |
| Benzel, EC | 1 |
| Mroz, TE | 1 |
| Krishnaney, AA | 1 |
| Arcidiaco, P | 1 |
| Ostadhadi, S | 1 |
| Kordjazy, N | 1 |
| Haj-Mirzaian, A | 1 |
| Ameli, S | 1 |
| Akhlaghipour, G | 1 |
| Dehpour, A | 1 |
| Barker, DJ | 1 |
| Root, DH | 1 |
| Morales, M | 1 |
| Wu, JL | 1 |
| Yu, SY | 1 |
| Wu, SH | 1 |
| Pochwat, B | 1 |
| Nowak, G | 1 |
| Szewczyk, B | 1 |
| Shepard, R | 1 |
| Page, CE | 1 |
| Coutellier, L | 1 |
| Mazarati, A | 1 |
| Sankar, R | 1 |
| Rosa, PB | 1 |
| Neis, VB | 1 |
| Ribeiro, CM | 1 |
| Moretti, M | 1 |
| Rodrigues, AL | 1 |
| Barde, S | 1 |
| Zhang, MD | 1 |
| Sun, J | 1 |
| Wang, T | 1 |
| Luo, H | 1 |
| Yang, Y | 1 |
| Svenningsson, P | 1 |
| Theodorsson, E | 1 |
| Hökfelt, TG | 1 |
| Xu, ZQ | 1 |
| Zhou, L | 1 |
| Ma, SL | 1 |
| Yeung, PK | 1 |
| Wong, YH | 1 |
| Tsim, KW | 1 |
| So, KF | 1 |
| Lam, LC | 1 |
| Chung, SK | 1 |
| Zhang, A | 1 |
| Zhao, B | 1 |
| Gan, J | 1 |
| Wang, G | 1 |
| Gao, F | 1 |
| Liu, B | 1 |
| Gong, T | 1 |
| Liu, W | 1 |
| Edden, RA | 2 |
| Setoyama, D | 1 |
| Kato, TA | 1 |
| Hashimoto, R | 1 |
| Kunugi, H | 1 |
| Hattori, K | 1 |
| Hayakawa, K | 1 |
| Sato-Kasai, M | 1 |
| Shimokawa, N | 1 |
| Kaneko, S | 1 |
| Yoshida, S | 1 |
| Goto, YI | 1 |
| Yasuda, Y | 1 |
| Yamamori, H | 1 |
| Ohgidani, M | 1 |
| Sagata, N | 1 |
| Miura, D | 1 |
| Kang, D | 1 |
| Kanba, S | 1 |
| Yuan, TF | 1 |
| Kumar, M | 1 |
| Martinez, EJ | 1 |
| Kolb, BL | 1 |
| Bell, A | 1 |
| Savage, DD | 1 |
| Allan, AM | 1 |
| Smith, SM | 1 |
| Culav-Sumić, J | 1 |
| Bosnjak, I | 1 |
| Pastar, Z | 1 |
| Jukić, V | 1 |
| Bodenmann, P | 1 |
| Pasche, O | 1 |
| Nanchen, D | 1 |
| Jaunin-Stalder, N | 1 |
| Marguerat, I | 1 |
| Chapuis, T | 1 |
| de Bosset, V | 1 |
| Cornuz, J | 1 |
| Czubak, A | 1 |
| Nowakowska, E | 1 |
| Kus, K | 1 |
| Sadowski, C | 1 |
| Matschay, A | 1 |
| Zink, M | 1 |
| Vollmayr, B | 3 |
| Gebicke-Haerter, PJ | 1 |
| Henn, FA | 2 |
| Küçükibrahimoğlu, E | 1 |
| Saygin, MZ | 1 |
| Calişkan, M | 1 |
| Kaplan, OK | 1 |
| Unsal, C | 1 |
| Gören, MZ | 1 |
| García-Campayo, J | 1 |
| Serrano-Blanco, A | 1 |
| Rodero, B | 1 |
| Magallón, R | 1 |
| Alda, M | 1 |
| Andrés, E | 1 |
| Luciano, JV | 1 |
| del Hoyo, YL | 1 |
| Garcia-Garcia, AL | 2 |
| Elizalde, N | 2 |
| Matrov, D | 1 |
| Harro, J | 1 |
| Wojcik, SM | 1 |
| Venzala, E | 2 |
| Ramírez, MJ | 3 |
| Del Rio, J | 1 |
| Tordera, RM | 3 |
| Stachowicz, K | 1 |
| Kłodzińska, A | 1 |
| Palucha-Poniewiera, A | 1 |
| Schann, S | 1 |
| Neuville, P | 1 |
| Lyoo, IK | 1 |
| Yoon, SJ | 1 |
| Musen, G | 1 |
| Simonson, DC | 1 |
| Weinger, K | 1 |
| Bolo, N | 1 |
| Ryan, CM | 1 |
| Kim, JE | 1 |
| Renshaw, PF | 1 |
| Jacobson, AM | 1 |
| Mamelak, M | 1 |
| Conner, BT | 1 |
| Hellemann, GS | 1 |
| Ritchie, TL | 1 |
| Noble, EP | 1 |
| Bandiera, FC | 1 |
| Arheart, KL | 1 |
| Caban-Martinez, AJ | 1 |
| Fleming, LE | 1 |
| McCollister, K | 1 |
| Dietz, NA | 1 |
| Leblanc, WG | 1 |
| Davila, EP | 1 |
| Lewis, JE | 1 |
| Serdar, B | 1 |
| Lee, DJ | 1 |
| Yildirim, K | 1 |
| Deniz, O | 1 |
| Gureser, G | 1 |
| Karatay, S | 1 |
| Ugur, M | 1 |
| Erdal, A | 1 |
| Senel, K | 1 |
| Henningsen, K | 1 |
| Jayatissa, MN | 1 |
| Hanff, TC | 1 |
| Furst, SJ | 1 |
| Minor, TR | 1 |
| Emir, B | 1 |
| Murphy, TK | 1 |
| Petersel, DL | 1 |
| Whalen, E | 1 |
| Taylor, MJ | 1 |
| Mannie, ZN | 1 |
| Norbury, R | 1 |
| Near, J | 1 |
| Cowen, PJ | 1 |
| Khundakar, A | 1 |
| Morris, C | 1 |
| Thomas, AJ | 1 |
| Appel, K | 1 |
| Rose, T | 1 |
| Fiebich, B | 1 |
| Kammler, T | 1 |
| Hoffmann, C | 1 |
| Weiss, G | 1 |
| Vlachou, S | 1 |
| Paterson, NE | 1 |
| Guery, S | 1 |
| Kaupmann, K | 1 |
| Froestl, W | 1 |
| Banerjee, D | 1 |
| Finn, MG | 1 |
| Markou, A | 1 |
| Chuang, CY | 1 |
| Shi, YC | 1 |
| You, HP | 1 |
| Lo, YH | 1 |
| Pan, TM | 1 |
| van Seventer, R | 1 |
| Serpell, M | 1 |
| Bach, FW | 2 |
| Morlion, B | 1 |
| Zlateva, G | 1 |
| Bushmakin, AG | 1 |
| Cappelleri, JC | 1 |
| Nimour, M | 1 |
| Calandre, EP | 1 |
| Morillas-Arques, P | 1 |
| Molina-Barea, R | 1 |
| Rodriguez-Lopez, CM | 1 |
| Rico-Villademoros, F | 1 |
| Kaufman, KR | 1 |
| Struck, PJ | 1 |
| Barbaccia, ML | 1 |
| Gu, CY | 1 |
| Biedermann, S | 1 |
| Weber-Fahr, W | 1 |
| Zheng, L | 1 |
| Hoyer, C | 1 |
| Gass, P | 1 |
| Ende, G | 2 |
| Sartorius, A | 2 |
| Luo, J | 1 |
| Min, S | 1 |
| Wei, K | 1 |
| Dong, J | 1 |
| Liu, YF | 1 |
| Möhler, H | 1 |
| Skirzewski, M | 1 |
| López, W | 1 |
| Mosquera, E | 1 |
| Betancourt, L | 1 |
| Catlow, B | 1 |
| Chiurillo, M | 1 |
| Loureiro, N | 1 |
| Hernández, L | 1 |
| Rada, P | 1 |
| Dhingra, D | 1 |
| Joshi, P | 1 |
| Gupta, A | 1 |
| Chhillar, R | 1 |
| Miklós, IH | 1 |
| Kovács, KJ | 1 |
| Martisova, E | 1 |
| Solas, M | 1 |
| Horrillo, I | 1 |
| Ortega, JE | 1 |
| Meana, JJ | 1 |
| Streeter, CC | 1 |
| Gerbarg, PL | 1 |
| Saper, RB | 1 |
| Ciraulo, DA | 1 |
| Brown, RP | 1 |
| Valente, MM | 1 |
| Bortolotto, V | 1 |
| Cuccurazzu, B | 1 |
| Ubezio, F | 1 |
| Meneghini, V | 1 |
| Francese, MT | 1 |
| Canonico, PL | 1 |
| Grilli, M | 1 |
| Biyik, Z | 1 |
| Solak, Y | 1 |
| Atalay, H | 1 |
| Gaipov, A | 1 |
| Guney, F | 1 |
| Turk, S | 1 |
| Leussis, MP | 1 |
| Brenhouse, HC | 1 |
| Zorumski, CF | 1 |
| Paul, SM | 1 |
| Izumi, Y | 1 |
| Covey, DF | 1 |
| Mennerick, S | 1 |
| Shaw, A | 1 |
| Brealy, J | 1 |
| Richardson, H | 1 |
| Muthukumaraswamy, SD | 1 |
| John Evans, C | 1 |
| Puts, NA | 1 |
| Singh, KD | 1 |
| Keedwell, PA | 1 |
| Reynolds, GP | 1 |
| Beasley, CL | 1 |
| Zhang, ZJ | 1 |
| Büyükokuroğlu, ME | 1 |
| Demirezer, LO | 1 |
| Güvenalp, Z | 1 |
| Carter, AC | 1 |
| Nicholas, JJ | 1 |
| Buijs, RM | 1 |
| van Eden, CG | 1 |
| Goncharuk, VD | 1 |
| Kalsbeek, A | 1 |
| RUSCAK, M | 2 |
| Ross, LE | 1 |
| Steiner, M | 1 |
| Jobe, PC | 2 |
| Sanacora, G | 1 |
| Rothman, DL | 1 |
| Mason, G | 1 |
| Krystal, JH | 1 |
| Baron, R | 1 |
| Morita, H | 1 |
| Uno, Y | 1 |
| Umemoto, T | 1 |
| Sugiyama, C | 1 |
| Matsumoto, M | 1 |
| Wada, Y | 1 |
| Ishizuka, T | 1 |
| Rasmussen, PV | 1 |
| Sindrup, SH | 1 |
| Jensen, TS | 1 |
| Moreno, FA | 1 |
| Kling, MA | 1 |
| Anderson, GM | 1 |
| Regenold, WT | 1 |
| Labiner, DM | 1 |
| Price, LH | 1 |
| Taylor, C | 1 |
| Fricker, AD | 1 |
| Devi, LA | 1 |
| Gomes, I | 1 |
| Garcia-Alloza, M | 1 |
| Tsang, SW | 1 |
| Gil-Bea, FJ | 1 |
| Francis, PT | 1 |
| Lai, MK | 1 |
| Marcos, B | 1 |
| Chen, CP | 1 |
| Miyata, S | 1 |
| Hirano, S | 1 |
| Kamei, J | 1 |
| Baghdoyan, HA | 1 |
| Rejas, J | 1 |
| Ribera, MV | 1 |
| Ruiz, M | 1 |
| Masrramón, X | 1 |
| Ciesielski, AS | 1 |
| Samson, S | 1 |
| Steinhoff, BJ | 1 |
| Aroniadou-Anderjaska, V | 1 |
| Qashu, F | 1 |
| Braga, MF | 1 |
| Hu, SY | 1 |
| Zhang, CH | 1 |
| Cao, MQ | 1 |
| Peng, GJ | 1 |
| Huang, CY | 1 |
| Grønli, J | 1 |
| Fiske, E | 1 |
| Murison, R | 1 |
| Bjorvatn, B | 1 |
| Sørensen, E | 1 |
| Ursin, R | 1 |
| Portas, CM | 1 |
| Sitruk-Ware, R | 1 |
| Bossemeyer, R | 1 |
| Bouchard, P | 1 |
| Mahlstedt, MM | 1 |
| Drevets, WC | 1 |
| Showraki, M | 1 |
| Owen, RT | 1 |
| Dambrova, M | 1 |
| Zvejniece, L | 1 |
| Liepinsh, E | 1 |
| Cirule, H | 1 |
| Zharkova, O | 1 |
| Veinberg, G | 1 |
| Kalvinsh, I | 1 |
| Oulis, P | 1 |
| Masdrakis, VG | 1 |
| Karakatsanis, NA | 1 |
| Karapoulios, E | 1 |
| Kouzoupis, AV | 1 |
| Konstantakopoulos, G | 1 |
| Soldatos, CR | 1 |
| Stein, DJ | 1 |
| Baldwin, DS | 1 |
| Baldinetti, F | 1 |
| Mandel, F | 1 |
| Li, CX | 1 |
| Gao, H | 1 |
| Pan, WJ | 1 |
| Xiang, Y | 1 |
| Lei, H | 1 |
| Daabees, TT | 1 |
| El-Din, MM | 1 |
| Zeitoun, R | 1 |
| Makar, AB | 1 |
| Petty, F | 1 |
| Sherman, AD | 1 |
| King, RB | 1 |
| Checkley, SA | 1 |
| Grahame-Smith, DG | 2 |
| Bonkowsky, HL | 1 |
| Schady, W | 1 |
| Cocchi, R | 2 |
| Zimmer, R | 1 |
| Teelken, AW | 1 |
| Meier, KD | 1 |
| Ackenheil, M | 1 |
| Zander, KJ | 1 |
| Gold, BI | 1 |
| Bowers, MB | 1 |
| Roth, RH | 1 |
| Sweeney, DW | 1 |
| Malatynska, E | 1 |
| De Leon, I | 1 |
| Allen, D | 1 |
| Yamamura, HI | 1 |
| Roy, A | 1 |
| Gigliotti, B | 1 |
| Multinu, A | 1 |
| Lai, VR | 1 |
| Fadda, F | 1 |
| Rossetti, ZL | 1 |
| Serretti, A | 1 |
| Macciardi, F | 1 |
| Cusin, C | 1 |
| Lattuada, E | 1 |
| Lilli, R | 1 |
| Di Bella, D | 1 |
| Catalano, M | 1 |
| Smeraldi, E | 1 |
| Kimbrell, TA | 1 |
| Dunn, RT | 1 |
| Piscitelli, S | 1 |
| Grothe, D | 1 |
| Vanderham, E | 1 |
| Corá-Locatelli, G | 1 |
| Post, RM | 1 |
| Ketter, TA | 1 |
| Brown, ES | 1 |
| Hong, SC | 1 |
| Khisti, RT | 1 |
| Chopde, CT | 1 |
| Greenberg, DB | 1 |
| Jonasch, E | 1 |
| Gadd, MA | 1 |
| Ryan, BF | 1 |
| Everett, JR | 1 |
| Sober, AJ | 1 |
| Mihm, MA | 1 |
| Tanabe, KK | 1 |
| Ott, M | 1 |
| Haluska, FG | 1 |
| Dailey, JW | 1 |
| Wernicke, JF | 1 |
| Prakash, HM | 1 |
| Sumant, K | 1 |
| Robichaud, M | 1 |
| Beauchemin, V | 1 |
| Lavoie, N | 1 |
| Dennis, T | 1 |
| Debonnel, G | 1 |
| Tornati, A | 1 |
| Mroji, T | 1 |
| Purdy, A | 1 |
| Hahn, A | 1 |
| Barnett, HJ | 1 |
| Bratty, P | 1 |
| Ahmad, D | 1 |
| Lloyd, KG | 1 |
| McGeer, EG | 1 |
| Perry, TL | 1 |
| Woelk, H | 1 |
| Vinar, O | 1 |
| Green, AR | 1 |
| Lynch, MA | 1 |
| Leonard, BE | 1 |
| Coupland, N | 1 |
| Glue, P | 1 |
| Nutt, DJ | 1 |
| Reynolds, EH | 1 |
| Guarneri, P | 1 |
| Guidotti, A | 1 |
| Costa, E | 1 |
| Mocaër, E | 1 |
| Suvorov, NF | 1 |
| Waintraub, L | 1 |
| Borsini, F | 1 |
| Mancinelli, A | 1 |
| D'Aranno, V | 1 |
| Evangelista, S | 1 |
| Meli, A | 1 |
| Poncelet, M | 1 |
| Martin, P | 1 |
| Danti, S | 1 |
| Simon, P | 1 |
| Soubrié, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Central Versus Peripheral GABA and Glutamate Biomarkers for Treatment Response During Two Infusions of Intravenous Ketamine for Treatment-Resistant Depression[NCT03573349] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2019-01-03 | Enrolling by invitation | ||
| Effects of Probiotics on Peripheral Immunity in Parkinson's Disease[NCT05173701] | 88 participants (Anticipated) | Interventional | 2021-11-22 | Enrolling by invitation | |||
| The Protective Role of Preoperative Stimulation of the Distal Limb of the Ileostomy Loop With GABA Before Ileostomy Closure[NCT05905393] | Phase 3 | 80 participants (Anticipated) | Interventional | 2023-06-30 | Not yet recruiting | ||
| Role of the Gut Microbiome as Determinant of Depression in Multiple Sclerosis Subjects[NCT05808101] | 120 participants (Anticipated) | Observational | 2022-01-27 | Recruiting | |||
| Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD[NCT02884908] | Phase 3 | 252 participants (Anticipated) | Interventional | 2016-09-30 | Active, not recruiting | ||
| Clinical Evaluation of the Antidepressant Effect of the Use of Probiotics in Bipolar Disorder and Possible Mediating Effects of Systemic and Intestinal Inflammatory Markers in the Microbiota[NCT05762887] | 84 participants (Anticipated) | Interventional | 2023-01-09 | Recruiting | |||
| Efficacy of Acceptance and Commitment Therapy (ACT) in Group in Fibromyalgia: a Randomized, Controlled Study.[NCT01611831] | 80 participants (Anticipated) | Interventional | 2012-01-31 | Active, not recruiting | |||
| A 9 Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Study Of Pregabalin (BID) In Subject With Posttraumatic Peripheral Neuropathic Pain[NCT00292188] | Phase 4 | 255 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Open Label Trial Concerning the Effectiveness of Trazodone in the Treatment of Fibromyalgia (Phase I) and Its Augmentation With Pregabalin in Trazodone Partial Responders (Phase II)[NCT00791739] | Phase 4 | 66 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Application of Vagal Stimulation by Cold Face Mask in Exposure and Response Prevention for Obsessive Compulsive Disorder[NCT02196090] | 10 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | |||
| A Phase I Randomized, Double-blinded, Placebo-controlled Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of HS-10353 in Chinese Adult Subjects[NCT05195203] | Phase 1 | 96 participants (Actual) | Interventional | 2021-01-27 | Completed | ||
| Comparing Therapeutic Efficacy and Cognitive Side Effects of Electroconvulsive Therapy (ECT) Using Ketamine Versus Methohexital Anesthesia[NCT01881763] | Phase 4 | 31 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| The Efficacy of Gabapentine and Splint Therapy in Bruxers: a Randomized Clinical Trial[NCT01255878] | 20 participants (Actual) | Interventional | 2010-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Hospital Anxiety and Depression Scale Anxiety Score (HADS-A) consists of 7 items that are assessed by a score of 0 = no anxiety to 3 = severe feeling of anxiety. The anxiety subscale determines a state of generalized anxiety (including anxious mood, restlessness, anxious thoughts, panic attacks). Score range = 0 to 21; higher scores indicate a greater intensity of anxiety (NCT00292188)
Timeframe: Week 8
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Pregabalin | 6.52 |
| Placebo | 7.36 |
Hospital Anxiety and Depression Scale Anxiety Score (HADS-A) consists of 7 items that are assessed by a score of 0 = no anxiety to 3 = severe feeling of anxiety. The anxiety subscale determines a state of generalized anxiety (including anxious mood, restlessness, anxious thoughts, panic attacks). Score range = 0 to 21; higher scores indicate a greater intensity of anxiety. (NCT00292188)
Timeframe: Week 8
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Pregabalin | 9.94 |
| Placebo | 11.63 |
"Hospital Anxiety and Depression Scale Depression Score (HADS-D) consists of 7 items that are assessed by a score of 0 = no depression to 3 = severe feeling of depression. The depression subscale focuses on the state of lost interest and diminished pleasure response (lowering of hedonic tone). Score range = 0 to 21; higher scores indicate a greater intensity of depression" (NCT00292188)
Timeframe: Week 8
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Pregabalin | 5.23 |
| Placebo | 6.20 |
Hospital Anxiety and Depression Scale (HADS-D) consists of 7 items that are assessed by a score of 0 = no depression to 3 = severe feeling of depression. The depression subscale focuses on the state of lost interest and diminished pleasure response (lowering of hedonic tone). Score range = 0 to 21; higher scores indicate a greater intensity of depression (NCT00292188)
Timeframe: Week 8
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Pregabalin | 12.04 |
| Placebo | 11.80 |
Number of subjects responding to have had optimal sleep. Optimal sleep is 1 item in the Medical Outcome Study (MOS)sleep scale, a patient-reported measure consisting of twelve items that assess the key constructs of sleep. Subjects were asked to recall sleep-related activities over the past week. (NCT00292188)
Timeframe: Week 8
| Intervention | participants (Number) |
|---|---|
| Pregabalin | 58 |
| Placebo | 45 |
Neuropathic Pain Symptom Inventory (NPSI) includes 10 descriptors (scale 0-10) of different pain symptoms & 2 temporal items assessing the duration of spontaneous ongoing and paroxysmal pain. A total intensity score is calculated by sub grouping the questions into five pain dimensions, summing the five sub groups, and converting into a percentage. (NCT00292188)
Timeframe: Week 8
| Intervention | percentage score on scale (Least Squares Mean) |
|---|---|
| Pregabalin | 33.29 |
| Placebo | 37.12 |
Daily Pain Diary scale : mean score from 11-point numerical scale of pain; range: 0 (no pain) to 10 (worst possible pain). Endpoint weekly mean pain score: mean of the last 7 available pain scores from a daily pain diary during double blind treatment. (NCT00292188)
Timeframe: each day of Week 8
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Pregabalin | 4.61 |
| Placebo | 5.23 |
11-point numerical scale with which the patient describes pain interference with sleep over past 24 hours; range: 0 (pain does not interfere with sleep) to 10 (pain completely interferes with sleep). Endpoint weekly mean score: mean of last 7 available scores from daily sleep interference diary during double-blind treatment. (NCT00292188)
Timeframe: Week 8
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Pregabalin | 2.93 |
| Placebo | 3.73 |
Clinical Global Impression of Change (CGIC): clinician's judgment of overall change in the patient's condition over a defined period on a 7-point scale; range: 1 Very Much Improved to 7 Very Much Worse. (NCT00292188)
Timeframe: Week 8
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| very much improved | much improved | minimally improved | no change | minimally worse | much worse | very much worse | |
| Placebo | 6 | 18 | 26 | 61 | 9 | 3 | 1 |
| Pregabalin | 11 | 33 | 36 | 33 | 5 | 4 | 1 |
Self-rated instrument to measure symptom severity and treatment outcome in post traumatic stress disorder (PTSD). Scale of 17 PTSD symptoms over previous week; frequency scale: 0 (not at all) to 4 (every day), and severity 0 (not at all distressing) to 4(extremely distressing). The total Davidson Trauma Scale score ranges from 0 to 136. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n=124, 124) | Week 8 (n=118, 120) | |
| Placebo | 20.90 | 18.47 |
| Pregabalin | 18.27 | 14.16 |
Self-rated instrument to measure symptom severity and treatment outcome in post traumatic stress disorder (PTSD). Scale of 17 PTSD symptoms over previous week; frequency scale: 0 (not at all) to 4 (every day), and severity 0 (not at all distressing) to 4(extremely distressing). The total Davidson Trauma Scale score ranges from 0 to 136. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline (n=116, 118) | Week 8 (n=112, 113) | |
| Placebo | 17.83 | 15.43 |
| Pregabalin | 15.55 | 11.71 |
Self-rated instrument to measure symptom severity and treatment outcome in post traumatic stress disorder (PTSD). Scale of 17 PTSD symptoms over previous week; frequency scale: 0 (not at all) to 4 (every day), and severity 0 (not at all distressing) to 4(extremely distressing). The total Davidson Trauma Scale score ranges from 0 to 136. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | score on scale (Mean) | |
|---|---|---|
| Baseline (n=116, 118) | Week 8 (n=112, 113) | |
| Placebo | 38.76 | 33.62 |
| Pregabalin | 34.57 | 26.18 |
Medical Outcome Study (MOS) is a patient-rated questionnaire consisting of 12 items that assess key constructs of sleep (7 subscales as well as a 9-item overall sleep problems index. MOS-Sleep Scale is scored from 0 to 100. A higher score indicates more disturbance. (NCT00292188)
Timeframe: Week 8
| Intervention | score on a scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Sleep Disturbance (n=117, 118) | Snoring (n=111, 118) | Awaken Short of Breath/Headache (n= 118, 117) | Sleep Quantity (n=117, 118) | Sleep Adequacy (n=119, 119) | Somnolence (n=116, 114) | Sleep Problems Index-6 (n=112, 111) | Sleep problems Index-9 (n=111, 107) | |
| Placebo | 46.45 | 37.87 | 20.66 | 6.48 | 44.61 | 32.33 | 51.72 | 42.98 |
| Pregabalin | 35.73 | 38.92 | 14.71 | 6.39 | 55.25 | 34.64 | 42.20 | 35.43 |
The number of subjects' responses to each of the 6 questions on the Medical Outcome Study Cognitive (MOS-Cog) subscale were summarized at baseline and Week 8. Category range: all of the time to none of the time. No formal statistical modeling was used. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: All of the Time | Baseline: Most of the Time | Baseline: A Good Bit of Time | Baseline: Some of the Time | Baseline: A Little of the Time | Baseline: None of the Time | Week 8: All of the Time | Week 8: Most of the Time | Week 8: A Good Bit of Time | Week 8: Some of the Time | Week 8: A Little of the Time | Week 8: None of the Time | |
| Placebo | 3 | 16 | 14 | 23 | 23 | 47 | 5 | 7 | 13 | 26 | 34 | 36 |
| Pregabalin | 5 | 3 | 13 | 24 | 39 | 42 | 4 | 10 | 8 | 22 | 34 | 42 |
The number of subjects' responses to each of the 6 questions on the Medical Outcome Study Cognitive (MOS-Cog) subscale were summarized at baseline and Week 8. Category range: all of the time to none of the time. No formal statistical modeling was used. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: All of the Time | Baseline: Most of the Time | Baseline: A Good Bit of the Time | Baseline: Some of the Time | Baseline: A Little of the Time | Baseline: None of the Time | Week 8: All of the Time | Week 8: Most of the Time | Week 8: A Good Bit of the Time | Week 8: Some of the Time | Week 8: A Little of the Time | Week 8: None of the Time | |
| Placebo | 4 | 14 | 14 | 29 | 26 | 39 | 7 | 5 | 16 | 27 | 33 | 33 |
| Pregabalin | 4 | 8 | 13 | 27 | 33 | 41 | 3 | 12 | 14 | 26 | 27 | 38 |
The number of subjects' responses to each of the 6 questions on the Medical Outcome Study Cognitive (MOS-Cog) subscale were summarized at baseline and Week 8. Category range: all of the time to none of the time. No formal statistical modeling was used. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | particpants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: All of the Time | Baseline: Most of the Time | Baseline: A Good Bit of the Time | Baseline: Some of the Time | Baseline: A Little of the Time | Baseline: None of the Time | Week 8: All of the Time | Week 8: Most of the Time | Week 8: A Good Bit of the Time | Week 8: Some of the Time | Week 8: A Little of the Time | Week 8: None of the Time | |
| Placebo | 6 | 12 | 7 | 15 | 35 | 51 | 3 | 11 | 6 | 23 | 27 | 51 |
| Pregabalin | 2 | 8 | 6 | 22 | 23 | 64 | 1 | 9 | 9 | 26 | 22 | 52 |
The number of subjects' responses to each of the 6 questions on the Medical Outcome Study Cognitive (MOS-Cog) subscale were summarized at baseline and Week 8. Category range: all of the time to none of the time. No formal statistical modeling was used. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: All of the Time | Baseline: Most of the Time | Baseline: A Good Bit of the Time | Baseline: Some of the Time | Baseline: A Little of the Time | Baseline: None of the Time | Week 8: All of the Time | Week 8: Most of the Time | Week 8: A Good Bit of Time | Week 8: Some of the Time | Week 8: A Little of the Time | Week 8: None of the Time | |
| Placebo | 10 | 14 | 8 | 23 | 33 | 38 | 9 | 7 | 11 | 31 | 35 | 28 |
| Pregabalin | 7 | 7 | 6 | 40 | 30 | 36 | 3 | 11 | 13 | 28 | 36 | 29 |
The number of subjects' responses to each of the 6 questions on the Medical Outcome Study Cognitive (MOS-Cog) subscale were summarized at baseline and Week 8. Category range: all of the time to none of the time. No formal statistical modeling was used. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: All of the Time | Baseline: Most of the Time | Baseline: A Good Bit of the Time | Baseline: Some of the Time | Baseline: A Little of the Time | Baseline: None of the Time | Week 8: All of the Time | Week 8: Most of the Time | Week 8: A Good Bit of the Time | Week 8: Some of the Time | Week 8: A Little of the Time | Week 8: None of the Time | |
| Placebo | 1 | 15 | 15 | 25 | 27 | 43 | 4 | 5 | 13 | 27 | 30 | 42 |
| Pregabalin | 5 | 6 | 5 | 20 | 42 | 48 | 3 | 10 | 11 | 23 | 32 | 41 |
The number of subjects' responses to each of the 6 questions on the Medical Outcome Study Cognitive (MOS-Cog) subscale were summarized at baseline and Week 8. Category range: all of the time to none of the time. No formal statistical modeling was used. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline: All of the Time | Baseline: Most of the Time | Baseline: A Good Bit of Time | Baseline: Some of the Time | Baseline: A Little of the Time | Baseline: None of the Time | Week 8: All of the Time | Week 8: Most of the Time | Week 8: A Good Bit of Time | Week 8: Some of the Time | Week 8: A Little of the Time | Week 8: None of the Time | |
| Placebo | 1 | 9 | 6 | 27 | 36 | 45 | 6 | 9 | 6 | 22 | 31 | 47 |
| Pregabalin | 2 | 6 | 3 | 31 | 33 | 51 | 4 | 6 | 12 | 28 | 31 | 39 |
Modified Brief Pain Inventory Short Form (m-BPI-sf): self-administered questionnaire to assess severity of pain (measured by 4 items)and impact of pain on daily functions (measured by 7 items)in past 24 hours. Items are rated on an 11-point scale ranging from 0 to 10, with higher scores indicating greater pain and/or interference due to pain. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| pain interference index Baseline (n=125, 126) | pain interference index Week 8 (n=120, 121) | pain severity index Baseline (n= 122, 125) | pain severity index Week 8 (n=120, 120) | |
| Placebo | 4.69 | 4.17 | 5.72 | 5.21 |
| Pregabalin | 4.57 | 3.31 | 5.36 | 4.20 |
Based on weekly mean daily pain rating score (DPRS), responders were defined as subjects with a >= 30% and >=50% reduction in weekly mean scores from baseline until endpoint (Week 8). Endpoint was calculated as the mean of the last 7 available pain scores from the daily pain diary while in the double-blind treatment phase. (NCT00292188)
Timeframe: Baseline, Week 8
| Intervention | participants (Number) | |
|---|---|---|
| 30% Responder | 50% Responder | |
| Placebo | 32 | 18 |
| Pregabalin | 50 | 30 |
Pain Treatment Satisfaction Scale (PTSS); Efficacy: measure of patient satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment. (NCT00292188)
Timeframe: Screening, Week 8
| Intervention | score on scale (Mean) | |
|---|---|---|
| Screening (n=112, 110) | End of Treatment (Week 8) (n=122, 121) | |
| Placebo | 42.73 | 37.88 |
| Pregabalin | 43.23 | 53.21 |
Pain Treatment Satisfaction Scale (PTSS); Impact of Current Pain Medication: measure of patient satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment. (NCT00292188)
Timeframe: Screening, Week 8
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Screening (n=113, 113) | End of Treatment (Week 8) (n=122, 121) | |
| Placebo | 53.60 | 42.56 |
| Pregabalin | 54.53 | 52.64 |
Pain Treatment Satisfaction Scale (PTSS); Medication Characteristics: measure of patient satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment. (NCT00292188)
Timeframe: Screening, Week 8
| Intervention | score on scale (Mean) | |
|---|---|---|
| Screening (n=112, 110) | End of Treatment (Week 8) (n=122, 121) | |
| Placebo | 59.39 | 70.39 |
| Pregabalin | 57.44 | 71.52 |
Pain Treatment Satisfaction Scale (PTSS); Satisfaction with Current Pain Medication: measure of patient satisfaction with treatment for acute or chronic pain. Response range:1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment. (NCT00292188)
Timeframe: Screening, Week 8
| Intervention | score on scale (Mean) | |
|---|---|---|
| Screening (n=112, 110) | Week 8 (n=122, 121) | |
| Placebo | 51.05 | 54.15 |
| Pregabalin | 50.33 | 62.36 |
Patient Global Impression of Change (PGIC): a patient-rated instrument that measures change in patient's overall status on a 7-point scale; range: 1 Very Much Improved to 7 Very Much Worse. (NCT00292188)
Timeframe: Week 8
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| very much improved | much improved | minimally improved | no change | minimally worse | much worse | very much worse | |
| Placebo | 6 | 22 | 26 | 52 | 10 | 7 | 2 |
| Pregabalin | 13 | 27 | 41 | 30 | 3 | 3 | 3 |
Daily Pain Diary scale : mean score from 11-point numerical scale of pain; range:0 (no pain) to 10 (worst possible pain). Mean of scores available for each week. (NCT00292188)
Timeframe: Baseline through Week 8
| Intervention | score on scale (Least Squares Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 1 (n=125, 125) | Week 2 (n=121, 119) | Week 3 (n=113, 116) | Week 4 (n=108, 108) | Week 5 (n=106, 104) | Week 6 (n=104, 101) | Week 7 (n=99, 99) | Week 8 (n=97, 97) | |
| Placebo | 5.79 | 5.64 | 5.44 | 5.27 | 5.26 | 5.34 | 5.26 | 5.24 |
| Pregabalin | 5.54 | 5.37 | 4.91 | 4.95 | 4.80 | 4.76 | 4.74 | 4.64 |
The items mostly range from a score of 0-4 but there are some questions that range from a score of 0-2. The maximum total score that can be reported is 76 and the lowest score is 0. Higher values represent a worse outcome. Items are summed together to compute the total score. Remission is defined as two consecutive Hamilton Rating Scale for Depression, 24 items (HRSD-24) scores < 10, and HRSD-24 total score does not increase > 3 points on the second consecutive HRSD-24, or remains < 6 at the last two consecutive treatments. HRSD-24 scores are used to define remission. (NCT01881763)
Timeframe: Days required to achieve remission (on average 3-4 weeks)
| Intervention | HRSD units (Mean) |
|---|---|
| Ketamine | 7.82 |
| Methohexital | 8.60 |
52 reviews available for gamma-aminobutyric acid and Depression
| Article | Year |
|---|---|
GABA System in Depression: Impact on Pathophysiology and Psychopharmacology.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; gamma-Aminobutyric Acid; Humans; Neur | 2022 |
Repetitive Transcranial Magnetic Stimulation-Associated Changes in Neocortical Metabolites in Major Depression: A Systematic Review.
Topics: Depression; Depressive Disorder, Major; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; N | 2022 |
Unravelling biological roles and mechanisms of GABA
Topics: Depression; gamma-Aminobutyric Acid; Humans; Memory Disorders; Receptors, GABA-B; Synapses | 2022 |
Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options.
Topics: Anti-Anxiety Agents; Benzodiazepines; Carrier Proteins; Cognition; Depression; Depression, Postpartu | 2023 |
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.
Topics: Antidepressive Agents; Depression; gamma-Aminobutyric Acid; Hallucinogens; Ketamine; Signal Transduc | 2023 |
Altered neurotransmission in stress-induced depressive disorders: The underlying role of the amygdala in depression.
Topics: Amygdala; Cholecystokinin; Depression; Depressive Disorder; gamma-Aminobutyric Acid; Humans; Synapti | 2023 |
GABA
Topics: Antidepressive Agents; Cognition; Depression; Depressive Disorder, Major; gamma-Aminobutyric Acid; H | 2023 |
Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders.
Topics: Brain Diseases; Cognition; Cognitive Dysfunction; Depression; gamma-Aminobutyric Acid; Humans; Inter | 2021 |
Somatostatin-Positive Gamma-Aminobutyric Acid Interneuron Deficits in Depression: Cortical Microcircuit and Therapeutic Perspectives.
Topics: Animals; Antidepressive Agents; Cerebral Cortex; Depression; gamma-Aminobutyric Acid; Humans; Intern | 2017 |
The role of gamma-aminobutyric acid in female depression
Topics: Animals; Antidepressive Agents; Brain; Depression; Female; gamma-Aminobutyric Acid; Humans; Hypothal | 2017 |
The H-Reflex as a Biomarker for Spinal Disinhibition in Painful Diabetic Neuropathy.
Topics: Animals; Biomarkers; Depression; Diabetic Neuropathies; gamma-Aminobutyric Acid; H-Reflex; Humans; N | 2018 |
Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders.
Topics: Animals; Antipsychotic Agents; Depression; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Receptors | 2019 |
Therapeutic potential of GABA(B) receptor ligands in drug addiction, anxiety, depression and other CNS disorders.
Topics: Anxiety; Central Nervous System Diseases; Depression; GABA Modulators; gamma-Aminobutyric Acid; Huma | 2013 |
Gabapentin withdrawal: case report in an older adult and review of the literature.
Topics: Aged; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Depression; Female; Gabapentin; gamm | 2013 |
BDNF and synaptic plasticity, cognitive function, and dysfunction.
Topics: Animals; Anxiety; Brain-Derived Neurotrophic Factor; Cognition; Depression; gamma-Aminobutyric Acid; | 2014 |
Gabapentinoids are effective in decreasing neuropathic pain and other secondary outcomes after spinal cord injury: a meta-analysis.
Topics: Amines; Analgesics; Anxiety; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Depression; Gaba | 2014 |
Emotion and mood adaptations in the peripartum female:complementary contributions of GABA and oxytocin.
Topics: Adaptation, Psychological; Affect; Animals; Anxiety; Depression; Emotions; Female; gamma-Aminobutyri | 2014 |
GABAergic Modulation in Diabetic Encephalopathy-Related Depression.
Topics: Animals; Brain Diseases; Depression; Diabetes Complications; gamma-Aminobutyric Acid; Humans; Neurot | 2015 |
Multiplexed neurochemical signaling by neurons of the ventral tegmental area.
Topics: Animals; Behavior; Depression; Dopamine; gamma-Aminobutyric Acid; Habenula; Humans; Neurons; Neurotr | 2016 |
Common Mechanisms Underlying Epileptogenesis and the Comorbidities of Epilepsy.
Topics: Animals; Brain; Comorbidity; Depression; Epilepsy; gamma-Aminobutyric Acid; Glutamic Acid; Humans; H | 2016 |
The Microbiome-Gut-Brain Axis in Health and Disease.
Topics: Animals; Autistic Disorder; Brain; Cytokines; Depression; Fatty Acids, Volatile; gamma-Aminobutyric | 2017 |
[Innovations in ambulatory care].
Topics: Acute Disease; Age Factors; Aged, 80 and over; Algorithms; Ambulatory Care; Analgesics; Angiotensin- | 2009 |
Narcolepsy and depression and the neurobiology of gammahydroxybutyrate.
Topics: Anesthetics, Intravenous; Animals; Depression; gamma-Aminobutyric Acid; Humans; Intracellular Signal | 2009 |
Corticotropin-releasing hormone, glutamate, and γ-aminobutyric acid in depression.
Topics: Corticotropin-Releasing Hormone; Depression; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Hypotha | 2011 |
Biochemical and anatomical substrates of depression and sickness behavior.
Topics: Adenosine; Adrenergic Uptake Inhibitors; Animals; Basal Ganglia; Brain; Depression; Disease Models, | 2010 |
Much excitement about antidepressants, DBI and c-FOS.
Topics: Animals; Antidepressive Agents; Anxiety; Depression; Diazepam Binding Inhibitor; gamma-Aminobutyric | 2011 |
The GABA system in anxiety and depression and its therapeutic potential.
Topics: Antidepressive Agents; Anxiety; Depression; GABA Agonists; gamma-Aminobutyric Acid; Humans; Neural P | 2012 |
Neurosteroids, stress and depression: potential therapeutic opportunities.
Topics: Animals; Brain; Depression; gamma-Aminobutyric Acid; Humans; Molecular Targeted Therapy; Neurotransm | 2013 |
The biological clock tunes the organs of the body: timing by hormones and the autonomic nervous system.
Topics: Animals; Autonomic Nervous System; Behavior; Biological Clocks; Circadian Rhythm; Depression; gamma- | 2003 |
A biopsychosocial approach to premenstrual dysphoric disorder.
Topics: Adult; Child; Child Abuse, Sexual; Depression; Diagnosis, Differential; Diagnostic and Statistical M | 2003 |
Common pathogenic mechanisms between depression and epilepsy: an experimental perspective.
Topics: Brain; Depression; Epilepsy; gamma-Aminobutyric Acid; Humans; Norepinephrine; Serotonin | 2003 |
Clinical studies implementing glutamate neurotransmission in mood disorders.
Topics: Animals; Brain Chemistry; Depression; gamma-Aminobutyric Acid; Glutamates; Humans; Magnetic Resonanc | 2003 |
Post-herpetic neuralgia case study: optimizing pain control.
Topics: Acetates; Aged; Amines; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2004 |
Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways.
Topics: Animals; Antidepressive Agents; Anxiety; Biogenic Monoamines; Depression; gamma-Aminobutyric Acid; G | 2005 |
Mechanisms regulating GABAergic inhibitory transmission in the basolateral amygdala: implications for epilepsy and anxiety disorders.
Topics: Adrenergic alpha-Agonists; Amygdala; Animals; Anticonvulsants; Anxiety Disorders; Depression; Dose-R | 2007 |
Preclinical and clinical properties of trimegestone: a potent and selective progestin.
Topics: Affect; Animals; Body Weight; Central Nervous System; Chemical Phenomena; Chemistry; Depression; Dru | 2007 |
Pregabalin: its efficacy, safety and tolerability profile in fibromyalgia syndrome.
Topics: Anticonvulsants; Anxiety Disorders; Cognition Disorders; Depression; Fatigue; Fibromyalgia; gamma-Am | 2007 |
Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anticonvulsants; Anxiety; Clinical Trials as Topic; D | 2008 |
Neuropharmacology of depression, anxiety, and pain.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety; Benzodiazepines; Brain; Cat | 1981 |
Neuroendocrine tests of monoamine function in man: a review of basic theory and its application to the study of depressive illness.
Topics: Adrenocorticotropic Hormone; Animals; Brain; Catecholamines; Depression; gamma-Aminobutyric Acid; Gr | 1980 |
Neurologic manifestations of acute porphyria.
Topics: Acute Disease; Aminolevulinic Acid; Animals; Central Nervous System; Depression; Electrophysiology; | 1982 |
Psychopharmacotherapy of anxiety in the first years of life.
Topics: Anxiety Disorders; Blood Glucose; Brain Chemistry; Delivery, Obstetric; Depression; Female; Fetal Bl | 1981 |
Chronic ethanol consumption: from neuroadaptation to neurodegeneration.
Topics: Acetylcholine; Adaptation, Physiological; Alcohol Amnestic Disorder; Alcohol Drinking; Alcohol-Relat | 1998 |
Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes.
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Antimanic Agents; Antineoplastic Agents; Bipolar Disor | 2000 |
A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders.
Topics: Animals; Anticonvulsants; Antidepressive Agents; Brain Chemistry; Causality; Depression; Disease Mod | 1999 |
The biology of depression.
Topics: Brain; Depression; Dopamine; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Imaging; Risk Facto | 2000 |
[On the mechanism of therapeutic actions of psychotropic drugs (author's transl)].
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzodiazepines; Biogenic Amines; | 1979 |
[The significance of endorphins and gamma-aminobutyric acid in clinical psychopharmacology (author's transl)].
Topics: Anxiety; Bipolar Disorder; Deficiency Diseases; Depression; Endorphins; gamma-Aminobutyric Acid; Hum | 1978 |
Challenge tests: assessment of the noradrenergic and GABA systems in depression and anxiety disorders.
Topics: Anxiety; Clonidine; Depression; gamma-Aminobutyric Acid; Growth Hormone; Humans; Hydrocortisone; Nor | 1992 |
Interictal psychiatric disorders. Neurochemical aspects.
Topics: Anticonvulsants; Biogenic Amines; Depression; Epilepsy; Folic Acid; gamma-Aminobutyric Acid; Humans; | 1991 |
[GABAergic substances in pharmacology].
Topics: 4-Aminobutyrate Transaminase; Animals; Anxiety; Depression; GABA Antagonists; gamma-Aminobutyric Aci | 1987 |
[GABA and mood disorders].
Topics: 4-Aminobutyrate Transaminase; Animals; Depression; Disease Models, Animal; gamma-Aminobutyric Acid; | 1987 |
15 trials available for gamma-aminobutyric acid and Depression
| Article | Year |
|---|---|
Allopregnanolone Treatment Improves Plasma Metabolomic Profile Associated with GABA Metabolism in Fragile X-Associated Tremor/Ataxia Syndrome: a Pilot Study.
Topics: Aged; Anxiety; Ataxia; Depression; Energy Metabolism; Fragile X Syndrome; gamma-Aminobutyric Acid; H | 2019 |
Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms.
Topics: Adult; Amines; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; C | 2014 |
Association between neuropathic pain, pregabalin treatment, and erectile dysfunction.
Topics: Adult; Analgesics; Coitus; Depression; Erectile Dysfunction; gamma-Aminobutyric Acid; Humans; Libido | 2014 |
Effect of pregabalin augmentation in treatment of patients with combat-related chronic posttraumatic stress disorder: a randomized controlled trial.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Anxiety; Combat Disorders; Depression; Double-Blind M | 2014 |
Effectiveness of the psychological and pharmacological treatment of catastrophization in patients with fibromyalgia: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Analgesics; Antidepressive Agents; Cognitive Behavioral Therapy; Combined M | 2009 |
Gabapentin monotherapy in patients with chronic radiculopathy: the efficacy and impact on life quality.
Topics: Administration, Oral; Adult; Amines; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; | 2009 |
Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Analgesics; Anxiety; Depression; Dose-Response Relation | 2010 |
Relationships between changes in pain severity and other patient-reported outcomes: an analysis in patients with posttraumatic peripheral neuropathic pain.
Topics: Analgesics; Anxiety; Depression; gamma-Aminobutyric Acid; Humans; Neuralgia; Pain Measurement; Prega | 2011 |
Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study.
Topics: Adult; Analgesics; Analysis of Variance; Anti-Anxiety Agents; Antidepressive Agents, Second-Generati | 2011 |
Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: a randomized prospective crossover trial.
Topics: Amines; Anti-Anxiety Agents; Calcium Channel Blockers; Cross-Over Studies; Cyclohexanecarboxylic Aci | 2013 |
Therapeutic outcome in neuropathic pain: relationship to evidence of nervous system lesion.
Topics: Acetates; Adult; Aged; Amines; Chi-Square Distribution; Cyclohexanecarboxylic Acids; Depression; Dos | 2004 |
Effect of vagus nerve stimulation on cerebrospinal fluid monoamine metabolites, norepinephrine, and gamma-aminobutyric acid concentrations in depressed patients.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Biogenic Monoamines; Case-Control Studies; Chrom | 2004 |
Psychometric properties of the MOS (Medical Outcomes Study) Sleep Scale in patients with neuropathic pain.
Topics: Adult; Aged; Amines; Analgesics; Anxiety; Cyclohexanecarboxylic Acids; Depression; Disability Evalua | 2007 |
Role of pivagabine in the treatment of climacteric syndrome.
Topics: Adult; Aged; Anxiety; Climacteric; Depression; Double-Blind Method; Female; gamma-Aminobutyric Acid; | 1997 |
Gabapentin does not alter single-dose lithium pharmacokinetics.
Topics: Acetates; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; Depression; Doubl | 1998 |
170 other studies available for gamma-aminobutyric acid and Depression
| Article | Year |
|---|---|
Saturation transfer MRI is sensitive to neurochemical changes in the rat brain due to chronic unpredictable mild stress.
Topics: 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; Animals; Cerebral Cortex; Chronic Disease | 2021 |
Alteration of the α5 GABA receptor and 5HTT lead to cognitive deficits associated with major depressive-like behaviors in a 14-day combined stress rat model.
Topics: Acetylcholinesterase; Animals; Cognition; Corticosterone; Depression; Depressive Disorder, Major; Di | 2023 |
Racemic ketamine treatment attenuates anterior cingulate cortex GABA deficits among remitters in treatment-resistant depression: A pilot study.
Topics: Depression; gamma-Aminobutyric Acid; Gyrus Cinguli; Humans; Ketamine; Pilot Projects | 2022 |
NAc-VTA circuit underlies emotional stress-induced anxiety-like behavior in the three-chamber vicarious social defeat stress mouse model.
Topics: Animals; Anxiety; Behavior, Animal; Dependovirus; Depression; Disease Models, Animal; Dopaminergic N | 2022 |
Baihe Dihuang (Lilium Henryi Baker and Rehmannia Glutinosa) decoction attenuates somatostatin interneurons deficits in prefrontal cortex of depression via miRNA-144-3p mediated GABA synthesis and release.
Topics: Animals; Antidepressive Agents; Depression; gamma-Aminobutyric Acid; In Situ Hybridization, Fluoresc | 2022 |
Microbiota alterations in proline metabolism impact depression.
Topics: Animals; Depression; gamma-Aminobutyric Acid; Gastrointestinal Microbiome; Humans; Mice; Microbiota; | 2022 |
Therapeutic effect of fecal microbiota transplantation on chronic unpredictable mild stress-induced depression.
Topics: Animals; Brain-Derived Neurotrophic Factor; Depression; Fecal Microbiota Transplantation; gamma-Amin | 2022 |
Pupil dilation during negative prediction errors is related to brain choline concentration and depressive symptoms in adolescents.
Topics: Adolescent; Biomarkers; Brain; Choline; Cholinergic Agents; Depression; gamma-Aminobutyric Acid; Glu | 2023 |
Changes in the TMS-evoked potential N100 in the dorsolateral prefrontal cortex as a function of depression severity in adolescents.
Topics: Adolescent; Depression; Depressive Disorder, Major; Dorsolateral Prefrontal Cortex; Electroencephalo | 2022 |
Minocycline Ameliorates Chronic Unpredictable Mild Stress-Induced Neuroinflammation and Abnormal mPFC-HIPP Oscillations in Mice.
Topics: Adenosine Triphosphate; Animals; Depression; Disease Models, Animal; gamma-Aminobutyric Acid; Glutam | 2022 |
Saffron essential oil ameliorates CUMS-induced depression-like behavior in mice via the MAPK-CREB1-BDNF signaling pathway.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Crocus; Depress | 2023 |
Antidepressant effects of cherry leaf decoction on a chronic unpredictable mild stress rat model based on the Glu/GABA-Gln metabolic loop.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Corticosterone; Depression; Disease Mod | 2022 |
Mechanism of lily bulb and Rehmannia decoction in the treatment of lipopolysaccharide-induced depression-like rats based on metabolomics study and network pharmacology.
Topics: Animals; Antidepressive Agents; Cytokines; Depression; Drugs, Chinese Herbal; Endocannabinoids; Fluo | 2022 |
Altered neurometabolite levels in the brains of patients with depression: A systematic analysis of magnetic resonance spectroscopy studies.
Topics: Aspartic Acid; Brain; Choline; Depression; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans | 2023 |
Altered neurometabolite levels in the brains of patients with depression: A systematic analysis of magnetic resonance spectroscopy studies.
Topics: Aspartic Acid; Brain; Choline; Depression; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans | 2023 |
Altered neurometabolite levels in the brains of patients with depression: A systematic analysis of magnetic resonance spectroscopy studies.
Topics: Aspartic Acid; Brain; Choline; Depression; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans | 2023 |
Altered neurometabolite levels in the brains of patients with depression: A systematic analysis of magnetic resonance spectroscopy studies.
Topics: Aspartic Acid; Brain; Choline; Depression; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans | 2023 |
Rice Germ Ameliorated Chronic Unpredictable Mild Stress-Induced Depressive-like Behavior by Reducing Neuroinflammation.
Topics: Animals; Antidepressive Agents; Caspases; Depression; Disease Models, Animal; gamma-Aminobutyric Aci | 2022 |
A role of GABA
Topics: Animals; Antidepressive Agents; Depression; GABA Antagonists; GABAergic Neurons; gamma-Aminobutyric | 2023 |
Hybrid molecules combining GABA-A and serotonin 5-HT
Topics: Antidepressive Agents; Depression; gamma-Aminobutyric Acid; Humans; Neuroinflammatory Diseases; Sero | 2023 |
DNMT1 Mediates Chronic Pain-Related Depression by Inhibiting GABAergic Neuronal Activation in the Central Amygdala.
Topics: Animals; Central Amygdaloid Nucleus; Chronic Pain; Depression; GABAergic Neurons; gamma-Aminobutyric | 2023 |
Effects of Escitalopram on the Functional Neural Circuits in an Animal Model of Adolescent Depression.
Topics: Animals; Citalopram; Depression; Disease Models, Animal; Escitalopram; gamma-Aminobutyric Acid; Glut | 2023 |
Caspase-1 affects chronic restraint stress-induced depression-like behaviors by modifying GABAergic dysfunction in the hippocampus.
Topics: Animals; Caspase 1; Depression; Depressive Disorder; gamma-Aminobutyric Acid; Hippocampus; Mice; Str | 2023 |
The role of neurotransmitters in mediating the relationship between brain alterations and depressive symptoms in patients with inflammatory bowel disease.
Topics: Brain; Depression; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Humans; Inflammatory Bowel Dis | 2023 |
Metabolites for monitoring symptoms and predicting remission in patients with depression who received electroconvulsive therapy: a pilot study.
Topics: Biomarkers; Depression; Depressive Disorder, Major; Electroconvulsive Therapy; gamma-Aminobutyric Ac | 2023 |
Electrical high frequency stimulation of the nucleus accumbens shell does not modulate depressive-like behavior in rats.
Topics: Animals; Behavior, Animal; Deep Brain Stimulation; Depression; Disease Models, Animal; gamma-Aminobu | 2020 |
Gamma-aminobutyric acid-producing lactobacilli positively affect metabolism and depressive-like behaviour in a mouse model of metabolic syndrome.
Topics: Adipose Tissue; Animals; Behavior, Animal; Body Weight; Cholesterol; Corticosterone; Depression; Dis | 2019 |
Ketamine rapidly reverses stress-induced impairments in GABAergic transmission in the prefrontal cortex in male rodents.
Topics: Animals; Antidepressive Agents; Depression; Disease Models, Animal; gamma-Aminobutyric Acid; Inhibit | 2020 |
Depression, GABA, and Age Correlate with Plasma Levels of Inflammatory Markers.
Topics: Adult; Age Factors; Aged; Biomarkers; Depression; Depressive Disorder, Major; Female; gamma-Aminobut | 2019 |
Glutamatergic and GABA-ergic abnormalities in First-episode depression. A 1-year follow-up 1H-MR spectroscopic study.
Topics: Depression; Depressive Disorder, Major; Follow-Up Studies; gamma-Aminobutyric Acid; Glutamic Acid; G | 2020 |
Neurotransmitter imbalance in serum of psoriatic patients in exacerbation stage with comorbid psychoemotional disorders.
Topics: Anxiety; Depression; gamma-Aminobutyric Acid; Humans; Neurotransmitter Agents; Psoriasis | 2020 |
Topics: Adult; Depression; Depressive Disorder, Major; gamma-Aminobutyric Acid; Glutamic Acid; Gyrus Cinguli | 2020 |
Blocking Astrocytic GABA Restores Synaptic Plasticity in Prefrontal Cortex of Rat Model of Depression.
Topics: Animals; Astrocytes; Atrophy; Depression; Disease Models, Animal; gamma-Aminobutyric Acid; Long-Term | 2020 |
Bifidobacterium adolescentis as a key member of the human gut microbiota in the production of GABA.
Topics: Animals; Anxiety; Bacterial Load; Bifidobacterium adolescentis; Depression; gamma-Aminobutyric Acid; | 2020 |
Blockade of GABA transporter-1 and GABA transporter-3 in the lateral habenula improves depressive-like behaviors in a rat model of Parkinson's disease.
Topics: Animals; Anisoles; Behavior, Animal; Depression; Dopamine; Dose-Response Relationship, Drug; Electro | 2020 |
Enrichment Environment Positively Influences Depression- and Anxiety-Like Behavior in Serotonin Transporter Knockout Rats through the Modulation of Neuroplasticity, Spine, and GABAergic Markers.
Topics: Animals; Animals, Genetically Modified; Anxiety; Behavior, Animal; Brain; Brain-Derived Neurotrophic | 2020 |
Effect of adzuki bean sprout fermented milk enriched in γ-aminobutyric acid on mild depression in a mouse model.
Topics: Animals; Cattle; Depression; Disease Models, Animal; Female; Fermentation; gamma-Aminobutyric Acid; | 2021 |
Depressive-like behaviors in mice with Imiquimod-induced psoriasis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; | 2020 |
Alterations of neurotransmitters and related metabolites in the habenula from CUMS-susceptible and -resilient rats.
Topics: Animals; Depression; Disease Susceptibility; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Haben | 2021 |
2-Pentadecyl-2-oxazoline ameliorates memory impairment and depression-like behaviour in neuropathic mice: possible role of adrenergic alpha2- and H3 histamine autoreceptors.
Topics: Amino Acid Sequence; Animals; Anxiety; Behavior, Animal; Chlorocebus aethiops; Cognition; COS Cells; | 2021 |
The Beneficial Role of
Topics: Animals; Apoptosis; Brain-Derived Neurotrophic Factor; Calcium Phosphates; Cognitive Dysfunction; De | 2021 |
Low-Dose Ozone Therapy Improves Sleep Quality in Patients with Insomnia and Coronary Heart Disease by Elevating Serum BDNF and GABA.
Topics: Brain-Derived Neurotrophic Factor; Catalase; Coronary Disease; Depression; gamma-Aminobutyric Acid; | 2021 |
Reciprocal control of obesity and anxiety-depressive disorder via a GABA and serotonin neural circuit.
Topics: Agouti-Related Protein; Anxiety; Depression; Depressive Disorder; gamma-Aminobutyric Acid; Humans; O | 2021 |
Exercise Ameliorates Fluoride-induced Anxiety- and Depression-like Behavior in Mice: Role of GABA.
Topics: Animals; Anxiety; Behavior, Animal; Depression; Female; Fluorides; gamma-Aminobutyric Acid; Mice; Se | 2022 |
Susceptibility to chronic immobilization stress-induced depressive-like behaviour in middle-aged female mice and accompanying changes in dopamine D1 and GABA
Topics: Animals; Behavior, Animal; Brain; Depression; Disease Models, Animal; Dopamine; Female; gamma-Aminob | 2021 |
Reduction of higher-order occipital GABA and impaired visual perception in acute major depressive disorder.
Topics: Depression; Depressive Disorder, Major; gamma-Aminobutyric Acid; Humans; Occipital Lobe; Proton Magn | 2021 |
A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration.
Topics: Depression; Depressive Disorder, Treatment-Resistant; gamma-Aminobutyric Acid; Glutamic Acid; Gyrus | 2021 |
Reductions in rostral anterior cingulate GABA are associated with stress circuitry in females with major depression: a multimodal imaging investigation.
Topics: Adult; Brain Mapping; Depression; Depressive Disorder, Major; Female; gamma-Aminobutyric Acid; Gyrus | 2021 |
Ergosteryl 2-naphthoate, An Ergosterol Derivative, Exhibits Antidepressant Effects Mediated by the Modification of GABAergic and Glutamatergic Systems.
Topics: Animals; Antidepressive Agents; Bicuculline; Central Nervous System; Depression; Dopamine; Dose-Resp | 2017 |
Impact of High-Fat Diet and Early Stress on Depressive-Like Behavior and Hippocampal Plasticity in Adult Male Rats.
Topics: Animals; Behavior, Animal; Biomarkers; Depression; Diet, High-Fat; gamma-Aminobutyric Acid; Glutamic | 2018 |
Improvement of Antioxidant Defences and Mood Status by Oral GABA Tea Administration in a Mouse Model of Post-Stroke Depression.
Topics: Affect; Animals; Depression; Disease Models, Animal; gamma-Aminobutyric Acid; Glutamates; Glutamic A | 2017 |
Early life stress and later peer distress on depressive behavior in adolescent female rats: Effects of a novel intervention on GABA and D2 receptors.
Topics: Animals; Animals, Newborn; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Depression; Depressive Dis | 2017 |
JIEYUANSHEN DECOCTION EXERTS ANTIDEPRESSANT EFFECTS ON DEPRESSIVE RAT MODEL VIA REGULATING HPA AXIS AND THE LEVEL OF AMINO ACIDS NEUROTRANSMITTER.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Chronic Disease; Corticosterone; Cortic | 2017 |
Increased glutamic acid decarboxylase expression in the hypothalamic suprachiasmatic nucleus in depression.
Topics: Aged; Aged, 80 and over; Arginine Vasopressin; Depression; Female; gamma-Aminobutyric Acid; Glutamat | 2017 |
Quality components and antidepressant-like effects of GABA green tea.
Topics: Animals; Antidepressive Agents; Camellia sinensis; Depression; Disease Models, Animal; Female; gamma | 2017 |
Effects of GABA microinjection into dorsal raphe nucleus on behavior and activity of lateral habenular neurons in mice.
Topics: Animals; Depression; Dorsal Raphe Nucleus; gamma-Aminobutyric Acid; Habenula; Hydroxyindoleacetic Ac | 2017 |
Periaqueductal Gray Glutamatergic Transmission Governs Chronic Stress-Induced Depression.
Topics: Anhedonia; Animals; Behavior, Animal; Depression; Disease Models, Animal; gamma-Aminobutyric Acid; G | 2018 |
Anterior cingulate cortex γ-aminobutyric acid deficits in youth with depression.
Topics: Adolescent; Anhedonia; Brain; Child; Depression; Depressive Disorder, Major; Female; gamma-Aminobuty | 2017 |
The sinonasal microbiota, neural signaling, and depression in chronic rhinosinusitis.
Topics: Adult; Aged; Bacteria; Bacterial Load; Chronic Disease; Depression; DNA, Bacterial; Dopamine; Female | 2018 |
Vulvodynia and depression - a case study.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Depression; Female; Gabapentin; gamma-Aminobutyric | 2017 |
Study on antidepressant activity of chiisanoside in mice.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; | 2018 |
Behavioral effects of toll-like receptor-4 antagonist 'eritoran' in an experimental model of depression: role of prefrontal and hippocampal neurogenesis and γ-aminobutyric acid/glutamate balance.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Depressive Disorder; | 2018 |
Prefrontal alterations in GABAergic and glutamatergic gene expression in relation to depression and suicide.
Topics: Adult; Depression; Female; Follow-Up Studies; gamma-Aminobutyric Acid; Gene Expression; Glutamic Aci | 2018 |
A new theory on GABA and Calcitonin Gene-Related Peptide involvement in Mal de Debarquement Syndrome predisposition factors and pathophysiology.
Topics: Adult; Calcitonin; Calcitonin Gene-Related Peptide; Depression; Female; gamma-Aminobutyric Acid; Hor | 2018 |
α-Mangostin exhibits antidepressant-like effects mediated by the modification of GABAergic, serotonergic and dopaminergic systems.
Topics: Animals; Antidepressive Agents; Brain; Depression; Dopamine; gamma-Aminobutyric Acid; Mice; Serotoni | 2020 |
GABA-modulating bacteria of the human gut microbiota.
Topics: Adult; Aged; Bacteria; Bacteroides; Brain; Cohort Studies; Depression; Depressive Disorder, Major; F | 2019 |
GABA-modulating bacteria of the human gut microbiota.
Topics: Adult; Aged; Bacteria; Bacteroides; Brain; Cohort Studies; Depression; Depressive Disorder, Major; F | 2019 |
GABA-modulating bacteria of the human gut microbiota.
Topics: Adult; Aged; Bacteria; Bacteroides; Brain; Cohort Studies; Depression; Depressive Disorder, Major; F | 2019 |
GABA-modulating bacteria of the human gut microbiota.
Topics: Adult; Aged; Bacteria; Bacteroides; Brain; Cohort Studies; Depression; Depressive Disorder, Major; F | 2019 |
[Altered Expression of Neurotransmitters Systems' Genes in the Ventral Tegmental Area of Depressive Male Mice: Data of RNA-Seq].
Topics: Animals; Anxiety; Depression; Disease Models, Animal; Dominance-Subordination; Dopamine; gamma-Amino | 2017 |
Minocycline ameliorates anxiety-related self-grooming behaviors and alters hippocampal neuroinflammation, GABA and serum cholesterol levels in female Sprague-Dawley rats subjected to chronic unpredictable mild stress.
Topics: Animals; Anxiety; Anxiety Disorders; Behavior, Animal; Cholesterol; Depression; Depressive Disorder; | 2019 |
The science of tea's mood-altering magic.
Topics: Adenosine; Affect; Alpha Rhythm; Animals; Antioxidants; Behavior; Beta Rhythm; Blood-Brain Barrier; | 2019 |
Adolescent stress increases depression-like behaviors and alters the excitatory-inhibitory balance in aged mice.
Topics: Aging; Animals; Anxiety; Brain; Depression; Depressive Disorder; gamma-Aminobutyric Acid; Hippocampu | 2019 |
Self-inflicted trans-oral intracranial stab wound.
Topics: Amines; Analgesics; Antidepressive Agents; Brain Injuries; Cerebellum; Citalopram; Cyclohexanecarbox | 2013 |
Neuropathic pain following sagittal split ramus osteotomy of the mandible: prevalence, risk factors, and clinical course.
Topics: Adult; Age Factors; Amines; Anticonvulsants; Antidepressive Agents, Tricyclic; Cohort Studies; Cyclo | 2013 |
Synergistic effects of celecoxib and bupropion in a model of chronic inflammation-related depression in mice.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Antidepressive Agents; Behavior, Animal; Brain-Derive | 2013 |
Dysfunctional glutamatergic and γ-aminobutyric acidergic activities in prefrontal cortex of mice in social defeat model of depression.
Topics: Animals; Carbon-13 Magnetic Resonance Spectroscopy; Depression; Depressive Disorder; Disease Models, | 2014 |
Ketamine reverses stress-induced depression-like behavior and increased GABA levels in the anterior cingulate: an 11.7 T 1H-MRS study in rats.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Chromatography, High Pressure Liquid; Depressi | 2014 |
Outcomes of pregabalin in lumbar-disease patients with depression.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Depression; Disability Evaluation; | 2014 |
The effect of GABAmimetics on the duration of immobility in the forced swim test in albino mice.
Topics: Alprazolam; Animals; Depression; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; | 2014 |
Downregulation of neuregulin 1-ErbB4 signaling in parvalbumin interneurons in the rat brain may contribute to the antidepressant properties of ketamine.
Topics: Animals; Antidepressive Agents; Brain; Depression; Down-Regulation; gamma-Aminobutyric Acid; Glutama | 2014 |
Chronic repetitive transcranial magnetic stimulation enhances GABAergic and cholinergic metabolism in chronic unpredictable mild stress rat model: ¹H-NMR spectroscopy study at 11.7T.
Topics: Animals; Choline; Chronic Disease; Depression; Food Preferences; gamma-Aminobutyric Acid; Hippocampu | 2014 |
Effects of D-series resolvins on behavioral and neurochemical changes in a fibromyalgia-like model in mice.
Topics: Analgesics; Animals; Antidepressive Agents; Brain; Depression; Disease Models, Animal; Docosahexaeno | 2014 |
Effects of single and combined gabapentin use in elevated plus maze and forced swimming tests.
Topics: Amines; Amitriptyline; Animals; Anticonvulsants; Anxiety; Cyclohexanecarboxylic Acids; Depression; D | 2014 |
Defects in dendrite and spine maturation and synaptogenesis associated with an anxious-depressive-like phenotype of GABAA receptor-deficient mice.
Topics: Animals; Anxiety; Brain-Derived Neurotrophic Factor; Cells, Cultured; Cerebral Cortex; Dendrites; De | 2015 |
Embryonic GABA(B) receptor blockade alters cell migration, adult hypothalamic structure, and anxiety- and depression-like behaviors sex specifically in mice.
Topics: Animals; Anxiety; Baclofen; Cell Movement; Depression; Embryo, Mammalian; Female; GABA-B Receptor An | 2014 |
[The interaction between gamma-aminobutyric acid and other related neurotransmitters in depression].
Topics: Animals; Brain; Depression; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Neurotransmitt | 2014 |
Mood regulation. GABA/glutamate co-release controls habenula output and is modified by antidepressant treatment.
Topics: Animals; Antidepressive Agents; Channelrhodopsins; Depression; Entopeduncular Nucleus; gamma-Aminobu | 2014 |
Shu‑Yu capsule, a Traditional Chinese Medicine formulation, attenuates premenstrual syndrome depression induced by chronic stress constraint.
Topics: Animals; Body Mass Index; Depression; Drugs, Chinese Herbal; Female; Fluoxetine; gamma-Aminobutyric | 2014 |
Presynaptic plasticity as a hallmark of rat stress susceptibility and antidepressant response.
Topics: Animals; Depression; gamma-Aminobutyric Acid; Male; Neuronal Plasticity; Rats; Rats, Wistar; Synapse | 2015 |
Psychotic and depressive symptoms after gabapentin treatment.
Topics: Amines; Cyclohexanecarboxylic Acids; Depression; Excitatory Amino Acid Antagonists; Female; Gabapent | 2015 |
Reward related neurotransmitter changes in a model of depression: An in vivo microdialysis study.
Topics: Animals; Depression; Disease Models, Animal; Dopamine; Dopamine Agents; gamma-Aminobutyric Acid; Glu | 2015 |
Prediction of quality of life improvements in patients with lumbar stenosis following use of membrane stabilizing agents.
Topics: Aged; Aged, 80 and over; Amines; Calcium Channel Blockers; Comorbidity; Cyclohexanecarboxylic Acids; | 2015 |
Antidepressive-like effects and antioxidant activity of green tea and GABA green tea in a mouse model of post-stroke depression.
Topics: Animals; Antidepressive Agents; Antioxidants; Brain; Camellia sinensis; Depression; Disease Models, | 2016 |
Involvement of NO/cGMP pathway in the antidepressant-like effect of gabapentin in mouse forced swimming test.
Topics: Amines; Animals; Antidepressive Agents; Behavior, Animal; Cyclic GMP; Cyclohexanecarboxylic Acids; D | 2016 |
A sensitive and practical RP-HPLC-FLD for determination of the low neuroactive amino acid levels in body fluids and its application in depression.
Topics: Aged; Aged, 80 and over; Amino Acids; Bipolar Disorder; Body Fluids; Case-Control Studies; Chromatog | 2016 |
Brain glutamic acid decarboxylase-67kDa alterations induced by magnesium treatment in olfactory bulbectomy and chronic mild stress models in rats.
Topics: Animals; Antidepressive Agents; Brain; Chronic Disease; Depression; Disease Models, Animal; gamma-Am | 2016 |
Sensitivity of the prefrontal GABAergic system to chronic stress in male and female mice: Relevance for sex differences in stress-related disorders.
Topics: Amygdala; Animals; Anxiety; Chronic Disease; Depression; Disease Models, Animal; Female; gamma-Amino | 2016 |
Antidepressant-like effects of ascorbic acid and ketamine involve modulation of GABAA and GABAB receptors.
Topics: Animals; Antidepressive Agents; Ascorbic Acid; Depression; Depressive Disorder, Major; Disease Model | 2016 |
Depression-like behavior in rat: Involvement of galanin receptor subtype 1 in the ventral periaqueductal gray.
Topics: Animals; Depression; Disease Models, Animal; gamma-Aminobutyric Acid; Locus Coeruleus; Male; Periaqu | 2016 |
Anxiety and depression with neurogenesis defects in exchange protein directly activated by cAMP 2-deficient mice are ameliorated by a selective serotonin reuptake inhibitor, Prozac.
Topics: Affect; Aged; Aged, 80 and over; Alzheimer Disease; Animals; Anxiety; Asian People; Behavior, Animal | 2016 |
GABA+ levels in postmenopausal women with mild-to-moderate depression: A preliminary study.
Topics: Case-Control Studies; Depression; Estrogens; Female; gamma-Aminobutyric Acid; Gyrus Cinguli; Humans; | 2016 |
Plasma Metabolites Predict Severity of Depression and Suicidal Ideation in Psychiatric Patients-A Multicenter Pilot Analysis.
Topics: 3-Hydroxybutyric Acid; Betaine; Biomarkers; Chromatography, Liquid; Citric Acid; Creatinine; Depress | 2016 |
Somatostatin-positive GABAergic interneuron: new targets for depression.
Topics: Depression; Depressive Disorder; GABAergic Neurons; gamma-Aminobutyric Acid; Humans; Interneurons; P | 2017 |
Protective effect of spermine against pentylenetetrazole kindling epilepsy induced comorbidities in mice.
Topics: Animals; Arginine; Avoidance Learning; Brain; Catecholamines; Comorbidity; Depression; Epilepsy; gam | 2017 |
Moderate perinatal arsenic exposure alters neuroendocrine markers associated with depression and increases depressive-like behaviors in adult mouse offspring.
Topics: Analysis of Variance; Animals; Animals, Newborn; Arsenic; Behavior, Animal; Corticosterone; Depressi | 2008 |
Pregabalin: a treatment for fibromyalgia and other painful conditions.
Topics: Analgesics; Anxiety; Depression; Dose-Response Relationship, Drug; Female; Fibromyalgia; gamma-Amino | 2008 |
Anxious depression and the stiff-person plus syndrome.
Topics: Anti-Inflammatory Agents; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Anxiety; Au | 2008 |
Effect of gabapentin on cognitive processes in rats not exposed and exposed to tobacco smoke during fetal life.
Topics: Amines; Animals; Anticonvulsants; Antidepressive Agents; Behavior, Animal; Cognition; Cyclohexanecar | 2008 |
Reduced expression of GABA transporter GAT3 in helpless rats, an animal model of depression.
Topics: Animals; Depression; Down-Regulation; GABA Plasma Membrane Transport Proteins; gamma-Aminobutyric Ac | 2009 |
The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression.
Topics: Antidepressive Agents, Second-Generation; Case-Control Studies; Chromatography, High Pressure Liquid | 2009 |
Increased vulnerability to depressive-like behavior of mice with decreased expression of VGLUT1.
Topics: Analysis of Variance; Animals; Brain; Brain Chemistry; Carbon Isotopes; Depression; Disease Models, | 2009 |
The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Cyclopentanes; Depression; Flumazenil; | 2009 |
Altered prefrontal glutamate-glutamine-gamma-aminobutyric acid levels and relation to low cognitive performance and depressive symptoms in type 1 diabetes mellitus.
Topics: Adult; Cognition Disorders; Depression; Diabetes Mellitus, Type 1; Female; gamma-Aminobutyric Acid; | 2009 |
Genetic, personality, and environmental predictors of drug use in adolescents.
Topics: Adolescent; Adolescent Behavior; Depression; Dopamine; Family; Female; gamma-Aminobutyric Acid; Gene | 2010 |
Fibromyalgia: poorly understood; treatments are disappointing.
Topics: Acetaminophen; Acupuncture Therapy; Amines; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Ant | 2009 |
Secondhand smoke exposure and depressive symptoms.
Topics: Air Pollution, Indoor; Chronic Disease; Cotinine; Depression; Depressive Disorder, Major; Environmen | 2010 |
Hippocampal GABAergic dysfunction in a rat chronic mild stress model of depression.
Topics: Action Potentials; Animals; Antidepressive Agents, Second-Generation; Citalopram; Dentate Gyrus; Dep | 2011 |
Elevated cortical glutamate in young people at increased familial risk of depression.
Topics: Adolescent; Cerebral Cortex; Depression; Depressive Disorder; Depressive Disorder, Major; Family; Fe | 2011 |
The immunohistochemical examination of GABAergic interneuron markers in the dorsolateral prefrontal cortex of patients with late-life depression.
Topics: Aged; Aged, 80 and over; Aging; Biomarkers; Calbindin 2; Case-Control Studies; Depression; Female; g | 2011 |
Modulation of the γ-aminobutyric acid (GABA) system by Passiflora incarnata L.
Topics: 4-Aminobutyrate Transaminase; Animals; Anxiety; Binding, Competitive; Cerebral Cortex; Depression; G | 2011 |
Both GABA(B) receptor activation and blockade exacerbated anhedonic aspects of nicotine withdrawal in rats.
Topics: Animals; Benzoates; Depression; Drug Synergism; GABA-B Receptor Agonists; GABA-B Receptor Antagonist | 2011 |
Antidepressant effect of GABA-rich monascus-fermented product on forced swimming rat model.
Topics: Animals; Antidepressive Agents; Biogenic Monoamines; Brain Chemistry; Depression; Disease Models, An | 2011 |
Gabapentin-induced sexual dysfunction.
Topics: Adult; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Depression; Gabapentin; gamma-Amino | 2011 |
[Rat orbital frontal (orbital frontal cortex, OFC) GABA B receptor mechanisms in stress and depression].
Topics: Animals; Depression; Frontal Lobe; gamma-Aminobutyric Acid; Humans; Male; Neuronal Plasticity; Neuro | 2011 |
Increase of hippocampal glutamate after electroconvulsive treatment: a quantitative proton MR spectroscopy study at 9.4 T in an animal model of depression.
Topics: Animals; Choline; Depression; Disease Models, Animal; Electroconvulsive Therapy; gamma-Aminobutyric | 2012 |
Propofol protects against impairment of learning-memory and imbalance of hippocampal Glu/GABA induced by electroconvulsive shock in depressed rats.
Topics: Animals; Cognition; Depression; Down-Regulation; Electroconvulsive Therapy; Electroshock; gamma-Amin | 2011 |
Enhanced GABAergic tone in the ventral pallidum: memory of unpleasant experiences?
Topics: Animals; Behavior, Animal; Bicuculline; Depression; Disease Models, Animal; Enzyme Inhibitors; GABA- | 2011 |
Possible involvement of monoaminergic neurotransmission in antidepressant-like activity of Emblica officinalis fruits in mice.
Topics: Animals; Antidepressive Agents; Ascorbic Acid; Biogenic Monoamines; Depression; Disease Models, Anim | 2012 |
Reorganization of synaptic inputs to the hypothalamic paraventricular nucleus during chronic psychogenic stress in rats.
Topics: Animals; Behavioral Symptoms; Chronic Disease; Corticosterone; Corticotropin-Releasing Hormone; Depr | 2012 |
Long lasting effects of early-life stress on glutamatergic/GABAergic circuitry in the rat hippocampus.
Topics: Age Factors; Animals; Antidepressive Agents, Second-Generation; Corticosterone; Cyclohexanols; Depre | 2012 |
Effects of yoga on the autonomic nervous system, gamma-aminobutyric-acid, and allostasis in epilepsy, depression, and post-traumatic stress disorder.
Topics: Allostasis; Anxiety Disorders; Autonomic Nervous System; Chronic Pain; Depression; Electric Stimulat | 2012 |
α2δ ligands act as positive modulators of adult hippocampal neurogenesis and prevent depression-like behavior induced by chronic restraint stress.
Topics: Amines; Animals; Calcium Channels; Cell Differentiation; Cyclohexanecarboxylic Acids; Depression; Ga | 2012 |
Social vs. environmental stress models of depression from a behavioural and neurochemical approach.
Topics: Animals; Anxiety; Behavior, Animal; Brain Stem; Depression; Disease Models, Animal; Dopamine; gamma- | 2013 |
Depressive-like behavior in adolescents after maternal separation: sex differences, controllability, and GABA.
Topics: Animals; Behavior, Animal; Depression; Female; Frontal Lobe; gamma-Aminobutyric Acid; Helplessness, | 2012 |
Marked reductions in visual evoked responses but not γ-aminobutyric acid concentrations or γ-band measures in remitted depression.
Topics: Adolescent; Adult; Brain; Brain Waves; Case-Control Studies; Depression; Evoked Potentials, Visual; | 2013 |
Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons.
Topics: Bipolar Disorder; Calbindin 2; Calbindins; Cerebral Cortex; Depression; gamma-Aminobutyric Acid; Hum | 2002 |
Sedative, anticonvulsant and behaviour modifying effects of Centranthus longiflorus ssp. longiflorus: a study of comparison to diazepam.
Topics: Adenosine; Animals; Anticonvulsants; Behavior, Animal; Caffeine; Central Nervous System Stimulants; | 2002 |
The importance of the complete history in the discovery of a potential suicide: a case report.
Topics: Acetates; Amines; Analgesics, Opioid; Anti-Anxiety Agents; Anti-Bacterial Agents; Cyclohexanecarboxy | 2003 |
INCREASE OF GAMMA-AMINOBUTYRIC ACID IN THE CEREBRAL CORTEX DURING ISCHAEMIA AND ITS RELATION TO EEG DEPRESSION.
Topics: Aminobutyrates; Carotid Arteries; Cerebral Cortex; Chromatography; Citric Acid Cycle; Depression; El | 1963 |
Changes in the level of gamma-aminobutyric acid (GABA) in the ischaemic brain of rats following application of some stimuli evoking spreading EEG depression.
Topics: Amino Acids; Animals; Brain; Brain Chemistry; Depression; Depressive Disorder; Electroencephalograph | 1962 |
[Unclear chronic aches. Often depression plays a part therein].
Topics: Acetates; Amines; Analgesics, Opioid; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Age | 2003 |
[Effect of gamma-aminobutyric acid-rich germinated brown rice on indexes of life-style related diseases].
Topics: Aged; Blood Glucose; Blood Pressure; Body Mass Index; Bone Density; Depression; Eating; Female; gamm | 2004 |
Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; Cognition Disorders; Depression; Female | 2006 |
Abnormal benzodiazepine receptor function in the depressive-like behavior of diabetic mice.
Topics: Animals; Behavior, Animal; Carbolines; Depression; Diabetes Mellitus, Experimental; Flumazenil; gamm | 2005 |
Hyperalgesia induced by REM sleep loss: a phenomenon in search of a mechanism.
Topics: Acetylcholine; Adenosine; Anxiety; Chronic Disease; Depression; Drug Therapy; Drug-Related Side Effe | 2006 |
Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study.
Topics: Adult; Anticonvulsants; Anxiety; Depression; Epilepsies, Partial; Female; gamma-Aminobutyric Acid; H | 2006 |
[Anti-depressive effect of Baisong tablets on the chronic mild unpredicted stress depression in rats].
Topics: Animals; Antidepressive Agents; Corticotropin-Releasing Hormone; Depression; Drugs, Chinese Herbal; | 2006 |
Extracellular levels of serotonin and GABA in the hippocampus after chronic mild stress in rats. A microdialysis study in an animal model of depression.
Topics: Analysis of Variance; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Depression; D | 2007 |
Elevated spectroscopic glutamate/gamma-amino butyric acid in rats bred for learned helplessness.
Topics: Animals; Behavior, Animal; Brain; Depression; Disease Models, Animal; gamma-Aminobutyric Acid; Gluta | 2007 |
Orbitofrontal cortex function and structure in depression.
Topics: Affective Disorders, Psychotic; Animals; Depression; Frontal Lobe; gamma-Aminobutyric Acid; Humans; | 2007 |
Pregabalin in the treatment of depression.
Topics: Adult; Depression; gamma-Aminobutyric Acid; Humans; Male; Pregabalin | 2007 |
Gamma-aminobutyric acid (GABA), Monograph.
Topics: Anxiety; Depression; Epilepsy; GABA Agents; gamma-Aminobutyric Acid; Humans; Hypnotics and Sedatives | 2007 |
Comparative pharmacological activity of optical isomers of phenibut.
Topics: Analgesics; Animals; Antidepressive Agents; Conflict, Psychological; Depression; GABA Agonists; GABA | 2008 |
Pregabalin in the discontinuation of long-term benzodiazepine use: a case-series.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Cognition; Depression; Female; gamma-Ami | 2008 |
Cerebral metabolic changes in a depression-like rat model of chronic forced swimming studied by ex vivo high resolution 1H magnetic resonance spectroscopy.
Topics: Animals; Behavior, Animal; Brain; Depression; gamma-Aminobutyric Acid; Glutamic Acid; Magnetic Reson | 2008 |
Injectable and oral contraceptive steroids in relation to some neurotransmitters in the rat brain.
Topics: Acetylcholine; Animals; Brain; Contraceptives, Oral; Contraceptives, Oral, Synthetic; Depression; Fe | 1981 |
GABAergic modulation of learned helplessness.
Topics: Amino Acids; Animals; Avoidance Learning; Behavior, Animal; Bicuculline; Depression; gamma-Aminobuty | 1981 |
The neuropharmacological effects of electroconvulsive shock and their relationship to the therapeutic effect of electroconvulsive therapy in depression.
Topics: Anesthesia, General; Animals; Antidepressive Agents; Apomorphine; Behavior, Animal; Brain; Corticost | 1984 |
Preliminary studies on CSF gamma-aminobutyric acid levels in psychiatric patients before and during treatment with different psychotropic drugs.
Topics: Adult; Depression; Female; gamma-Aminobutyric Acid; Humans; Male; Mental Disorders; Middle Aged; Psy | 1980 |
GABA levels in CSF of patients with psychiatric disorders.
Topics: Adult; Aged; Bipolar Disorder; Depression; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Age | 1980 |
Effects of amitriptyline on GABA-stimulated 36CI- uptake in relation to a behavioral model of depression.
Topics: Amitriptyline; Analysis of Variance; Animals; Chlorine; Depression; Disease Models, Animal; Dominanc | 1995 |
Neuropeptides in relation to suicidal behavior in depression.
Topics: Adult; Corticotropin-Releasing Hormone; Depression; Diazepam; Female; gamma-Aminobutyric Acid; Human | 1993 |
GABAA alpha-1 subunit gene not associated with depressive symptomatology in mood disorders.
Topics: Adult; Anxiety; Bipolar Disorder; Delusions; Depression; DNA; Female; gamma-Aminobutyric Acid; Genet | 1998 |
Antidepressant-induced bruxism successfully treated with gabapentin.
Topics: Acetates; Amines; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Bipolar Disorder; B | 1999 |
Serotonergic agents modulate antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice.
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Depression; Drug Interactions; gamma-Aminobutyr | 2000 |
Effects of bilateral olfactory bulbectomy on N-methyl-D-aspartate receptor function: autoradiographic and behavioral studies in the rat.
Topics: Animals; Binding Sites; Brain; Denervation; Depression; Disease Models, Animal; Dizocilpine Maleate; | 2001 |
Psychic dependence? A different formulation of the problem with a view to the reorientation of therapy for chronic drug addiction.
Topics: Aminobutyrates; Antidepressive Agents, Tricyclic; Depression; gamma-Aminobutyric Acid; Glutamine; Hu | 1977 |
Familial fatal Parkinsonism with alveolar hypoventilation and mental depression.
Topics: Brain; Brain Chemistry; Depression; Dopa Decarboxylase; Dopamine; gamma-Aminobutyric Acid; Glutamate | 1979 |
[The metabolically disordered neuron].
Topics: Adenosine Triphosphate; Antidepressive Agents; Biogenic Amines; Brain; Depression; Energy Metabolism | 1979 |
Processes regulating the functional activity of brain 5-hydroxytryptamine: results of animal experimentation and their relevance to the understanding and treatment of depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Depression; Dopamine; gamma-Aminobutyric Ac | 1978 |
Changes in brain gamma-aminobutyric acid concentrations following acute and chronic amphetamine administration and during post amphetamine depression.
Topics: Animals; Brain; Chlorpromazine; Depression; Dextroamphetamine; gamma-Aminobutyric Acid; Humans; Male | 1978 |
On the processing of diazepam binding inhibitor (DBI) in human brain.
Topics: Amino Acid Sequence; Animals; Anxiety Disorders; Brain; Depression; Diazepam Binding Inhibitor; gamm | 1990 |
[The role of the monoaminergic systems of the neostriatum and limbic structures in the pathology of higher nervous activity].
Topics: Animals; Brain Chemistry; Caudate Nucleus; Conditioning, Classical; Depression; Dopamine; Escape Rea | 1988 |
On the role of endogenous GABA in the forced swimming test in rats.
Topics: Aminooxyacetic Acid; Animals; Brain; Depression; Disease Models, Animal; gamma-Aminobutyric Acid; Ma | 1988 |
Noradrenergic rather than GABAergic processes as the common mediation of the antidepressant profile of GABA agonists and imipramine-like drugs in animals.
Topics: Animals; Antidepressive Agents; Brain; Depression; Disease Models, Animal; gamma-Aminobutyric Acid; | 1987 |